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Little, Laura G., M.S., Spring 2008      Chemistry 
 
Response of a NEIL1 deficient murine epithelial cell line to chromate. 
. 
Chairperson:  Dr. Kent D. Sugden 
 
DNA is constantly exposed to oxidants which can lead to nucleobase 
damage.  Chromium is of particular interest as a DNA oxidant because of its abundance in 
the environment and the ease with which it can be taken into a cell.  Chromate, Cr(VI), 
ions are taken up by a cell through relatively non-selective anion channels which 
normally regulate uptake of phosphate and sulfate ions.  Once in the cell, chromate ions 
are reduced by intracellular reductants such as ascorbate and glutathione to Cr(III).  
Highly reactive Cr(V) and Cr(IV) species are created during this transition which are able 
to directly oxidize DNA, particularly guanine residues due to their low reduction potential 
relative to the other three bases, adenine, thymine, and cytosine.  7,8-dihydro-8-oxo-2’-
deoxyguanosine (8-oxoG) has previously been viewed as the primary marker of oxidative 
stress but the reduction potential of 8-oxoG is even lower than that of the parent guanine 
residue making it a prime target for further oxidative events.  Spiroiminodihydantoin (Sp) 
is one product of these further oxidative events.  
The NEIL1 base excision repair (BER) glycosylase has been shown to 
recognize and cleave the oxidative DNA lesion Sp.  NEIL1 belongs to a family of three 
mammalian DNA glycosylases Neil1, Neil2, and Neil3.  NEIL1 and NEIL2 are both able 
to recognize and cleave the oxidative lesion Sp in single stranded DNA in vitro.  In 
duplex DNA, only NEIL1 is able to recognize and cleave the Sp lesion.   
A Neil1 -/- mouse model was recently developed and displayed a range of 
metabolic disorders that could be linked to oxidative DNA damage.  These altered 
phenotypes included obesity, fatty liver, kidney vacuolization, hyperleptinemia, 
hyperinsulinemia, and increased mitochondrial DNA damage and deletions.  Using 
kidney epithelial cells from the Neil1 -/- mouse model, we have shown that a NEIL1 
glycosylase deficiency alters toxicity, cell cycle arrest and apoptosis patterns following 
exposure to chromate.         
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1 
CHAPTER 1 
Introduction 
 
1.1 Chromium – An Occupational and Environmental Health Hazard 
 
Hexavalent chromium – Cr(VI) - is a well established human carcinogen.  The 
first evidence showing that hexavalent chromium may be a carcinogen was a high 
incidence of nasal tumors reported in the late 19th century in chrome pigment workers in 
Scotland.1  Cr(VI) has also been shown to cause lung cancer.  In the 20th century chromate 
workers in Germany, the United Kingdom, and the United States showed an increased 
risk for the development of lung cancer.2-5  Industries in which workers are still exposed 
to Cr(VI) today include chrome plating, stainless steel welding, leather tanning, and 
chrome pigment and dye production.6  Occupational hazards of hexavalent chromium are 
made clear by the enhanced incidence of cancer due to workplace exposure but 
environmental exposure from years of industrial dumping of chrome waste is also a major 
factor to be considered in the overall risk to human health posed by Cr(VI).   
Chromium exists at an average level of 100 mg/kg in the earth’s crust.  The 
majority of that chromium exists in the trivalent – Cr(III) – form.7  What little Cr(VI) that 
is present exists mainly as chromate (CrO42-) and is much more mobile than Cr(III) 
compounds due to its significantly higher solubility.7  Industrial use of chromate 
chemicals that contributes to environmental contamination includes its use in cooling 
towers to prevent rust accumulation, waste from the manufacture and use of chromate 
compounds, and the mist of chromic acid produced in the chrome-plating industry.8  This 
chromate waste can travel over significant distances if introduced into a water source.  
Some of the chromate may be reduced to Cr(III), most of which will precipitate as 
Cr(OH)3-3H2O but the portion that remains in the hexavalent form will be carried 
downstream.7,9  People that work with chromate compounds and those that encounter 
chromate compounds in the environment run a higher risk of developing cancer than the 
general population.  The mode of action for the carcinogenicity observed with chromate 
needs to be more clearly understood in order to reduce the risks associated with human 
interaction with chromate compounds. 
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Chromium, especially hexavalent chromium, is of great interest not only because 
of its toxic effects on humans but also because of the high risk of exposure to hexavalent 
chromium that still exists for the general public.  In 1992 the drinking water standard for 
total chromium was lowered to 0.1 ppm due to the emergence of new information about 
amounts of chromium being released into the environment.10  Between the years 1987 and 
1993, there were 2,876,055 pounds of chromium released into bodies of water in the 
United States and 196,880,624 pounds released on land.  There are currently four 
locations in Montana alone that are active superfund sites containing chromium (Table 
1.1).10  The contamination stems from the mining, smelting, and wood treatment 
industries.  There are 719 superfund sites nationwide with chromium listed as at least one 
of the contaminants present.11  Not only is the Environmental Protection Agency still 
concerned about chromium exposure, so too is the Occupational Safety and Health 
Administration (OSHA).  In February of 2006, OSHA settled on a new standard for 
occupational exposure to hexavalent chromium.  The standard was lowered from 52 to 5 
µg/m3 of air as an 8 hour time-weighted average for hexavalent chromium.12 
 
 
Table 1.1 – Active superfund sites in Montana containing chromium.10 
 
City Site Name Date of Listing 
Anaconda Anaconda Co. Smelter Sept. 8, 1983 
Butte Montana Pole and Treating July 22, 1987 
Butte Silver Bow Creek/Butte Area Sept. 8, 1983 
Libby Libby Ground Water Contamination Sept. 8, 1983 
 
 
 
1.2 Chromium – Oxidative DNA Damage 
 
 There are a several theories that have been proposed to explain the genotoxicity of 
chromium.  These include the formation of DNA adducts, single strand breaks, DNA-
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protein crosslinks, and oxidized nucleobases.13  All of these theories concerning the 
genotoxicity of chromium recognize Cr(VI) and not Cr(III) as the genotoxic chromium 
species.  This is because Cr(VI) ions, unlike Cr(III) ions, are taken up by the cell through 
relatively non-selective anion channels14 which normally regulate the uptake of phosphate 
and sulfate ions required for the synthesis of proteins and DNA.  Cr(III) ions are able to 
cross the cell membrane but rely solely on diffusion and are therefore taken up 
approximately three orders of magnitude more slowly than Cr(VI) ions.15  Chromate, 
phosphate and sulfate ions are all of a similar size and share the same charge and 
tetrahedral geometry (Figure 1.1).1  Once in the cell, Cr(VI) is quickly reduced by a 
variety of intracellular reductants including ascorbic acid and reduced thiols such as 
cysteine and glutathione.  Ascorbic acid is the most kinetically favored of these reductants 
and is therefore generally regarded as the major intracellular reductant of Cr(VI).16  The 
rapid reduction of Cr(VI) to Cr(V), Cr(IV), and finally to Cr(III) creates a concentration 
gradient across the cell membrane that favors the continual uptake of Cr(VI) from the 
extracellular matrix.   
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Figure 1.1 – Phosphate and chromate ions at physiological pH. 
 
 
 Cr(VI) can gain access to the cell but it is not Cr(VI) that causes damage to 
nucleic acids.  The reduced forms of Cr(VI) – Cr(V), Cr(IV), and Cr(III) are the species 
which interact with DNA.17   Cr(V) species have been shown to directly oxidize the 
nucleobases.18  The highly reactive Cr(V) species can abstract an electron from the 
conjugated ring system of DNA.19  Guanine residues are preferentially attacked because 
of their low one-electron reduction potential relative to that of the other three bases (Table 
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1.2).20-22  That reduction potential becomes even lower for the 5’ guanine residue when a 
run of guanine residues is present in a DNA sequence (Table 1.2).  The most widely 
recognized lesion formed by a one electron abstraction from a guanine residue is 7,8-
dihydro-8-oxo-2’-deoxyguanosine (8-oxoG) (Figure 1.2).20  When an electron is 
abstracted from the C8 position of a guanine, a radical cation is formed.  Water then acts 
as a nucleophile and attacks the charged C8 position.  The C8 hydrogen leaves along with 
a second electron giving an 8-oxoG residue.19   
 An alternate explanation for Cr(VI) induced oxidative DNA damage that has also 
been extensively investigated involves the formation of reactive oxygen species (ROS). 
Through Fenton-like reactions (Figure 1.3) with H2O2, both Cr(III)20 and Cr(VI)21,22 have 
been shown to be capable of producing hydroxyl radicals which can then attack the 
electron rich aromatic rings of the nucleobases.  This pathway is favorable in the presence 
of high concentrations of H2O2 ([0.5 mM – 27 mM])20-22 which have been used for in 
vitro studies.  Under normal physiological conditions, the concentration of H2O2 in a cell 
is much lower than 1 mM (in the µM range)23 indicating that oxidation of nucleic acids by 
ROS is likely to play a very small role in the overall oxidative damage that has been 
observed in cells exposed to Cr(VI).    
 
 
Table 1.2 – Reduction potentials for nucleosides and DNA sequences.24,26,27  The 5' 
guanine in a run of guanine residues has a lower reduction potential than a single guanine 
and the 8-oxoG has a lower reduction potential than the parent guanine residue. 
 
Nucleoside Eo (V vs NHE) DNA Sequence Eo (V vs NHE) 
Guanine (G) 1.29 GGG 0.64 
Adenine (A) 1.42 GG 0.82 
Cytosine (C) 1.6 GA 1.00 
Thymine (T) 1.7 GC 1.15 
8-oxoG 0.74 GT 1.16 
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Figure 1.2 – Single electron oxidation of a guanine residue to give the 8-oxoG lesion.19 
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Figure 1.3 – The Fenton-like reactions that have been proposed for chromium 
metabolism within a cell.  Hydroxyl radicals formed in these reactions could directly 
abstract an electron from DNA.   
 
 
8-oxoG has previously been viewed as the primary marker of oxidative stress.28 
The 8-oxoG lesion, if allowed to persist in the genome, is mutagenic as it can cause a 
mispairing with adenine during DNA replication causing G:C→T:A transversion 
mutations.29  However, the one-electron reduction potential of 8-oxoG is even lower than 
that of the parent guanine residue making it a prime target for further oxidative events 
(Table 1.2).  It would be highly unlikely for an electron to be directly abstracted from the 
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same DNA base twice but further oxidized products of 8-oxoG have been observed both 
in vitro and in cellular systems.30,31  Charge transfer is one mechanism that has been 
proposed to explain how two oxidative events can occur at the same base in a DNA 
sequence.  This mechanism proposes that an electron hole will be translated through the 
DNA to a sink – a nucleoside with a lower reduction potential than that of the neighboring 
nucleosides.26  The stacked bases create an array of overlapping π-orbitals that facilitate 
charge transfer through a DNA sequence.32 8-oxoG lesions can act as a sink for charge 
transfer because of their lower reduction potential relative to that of the four undamaged 
nucleosides.  When an 8-oxoG lesion is present within approximately 10-20 base pairs 
(greatly dependent on the DNA sequence)32 of the site of an electron abstraction from a 
nucleobase, the resultant charge can be transferred to an 8-oxoG residue resulting in a 
secondary oxidative event at the same base.   
 The low reduction potential of 8-oxoG along with its ability to act as a sink for 
charge transfer in a DNA sequence indicates that 8-oxoG is not likely to be the end 
product of an oxidative attack on the nucleobases.  One of the secondary lesions that has 
been shown to form both in vitro and in cellular systems is spiroiminodihydantoin 
(Sp).30,31  Sp, like 8-oxoG, can produce G:C→T:A transversion mutations but at a higher 
level.  In addition to the G:C→T:A transversion mutations, Sp can also produce 
G:C→C:G transversion mutations and polymerase arrest both in vitro and in cellular 
systems.33-35  The formation of Sp helps to explain the high level of mutations observed in 
Cr(VI) treated systems that cannot be accounted for by the formation of 8-oxoG lesions 
alone.   
 There are a host of further oxidized lesions that have been proposed to form 
following oxidation of DNA.  Some of the more common examples are shown in figure 
1.4.  Sp is a further oxidized lesion of particular interest because it has been observed to 
form in cellular systems,31 it has an increased mutagenic potential over that of 8-oxoG, 
and it has been shown to accumulate in much larger quantities than 8-oxoG in an 
Escherichia coli repair deficient model exposed to Cr(VI).31  Accumulation of Sp in a 
cellular system is possible because while water may not be the strongest nucleophile 
present in a cell it is the most abundant and can thus attack the radical cation formed 
when an electron is abstracted from an 8-oxoG residue (Figure 1.5).30  Further more, Sp 
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forms ideally at     37o C and at pH 7.430 which are both biologically relevant parameters.  
Because it is more favorable for further oxidized lesions such as Sp to be the end product 
of an oxidative event at a nucleobase, these lesions may serve as more relevant 
biomarkers for oxidative stress in a cellular system.   
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Figure 1.4 – A sample of some of the further oxidized guanine lesions that have been 
proposed to form in oxidatively damaged DNA. 
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Figure 1.5 – Single electron reduction of 8-oxoG to give the Sp lesion.30 
 
 
1.3 Base Excision Repair 
  
 Cells have three types of repair systems in place to deal with damaged or 
mismatched DNA bases which are conserved from prokaryotes to mammals.36  They 
include base excision repair, nucleotide excision repair, and mismatch repair.37  Base 
excision repair (BER) is the direct removal of a single nucleobase that is damaged or 
mismatched.37  Nucleotide excision repair (NER) is the direct removal of a short sequence 
of DNA (~25-30 bases) containing a damaged or mismatched base(s).37  Mismatch repair 
(MMR) is the direct removal of a large sequence of DNA (up to a few kilodaltons in size) 
that contains a mismatched base(s) following DNA replication.37  Cells primarily use the 
BER pathway to remove oxidative DNA base lesions.38  The BER pathway involves a 
DNA glycosylase that recognizes an individual damaged base.  The damaged base is then 
flipped out of the DNA strand and cleaved at the glycosidic bond forming an 
apurinic/apyrimidinic (AP) site.38  The DNA glycosylase binds to the 1’ carbon of the 
deoxyribose subunit allowing the damaged nucleobase to leave and a Schiff base to be 
formed between the abasic site and the BER enzyme.38  Many DNA glycosylases do not 
further process the AP site but some glycosylases involved in repair of oxidized DNA 
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base lesions possess lyase activity allowing them to further degrade the AP site.39  Further 
degradation leads to release of the DNA glycosylase and the formation of a 5’-
phosphomonoester and a 3’-unsaturated deoxyribose phosphate residue, also referred to 
as the β-elimination product (Figure 1.6 c).39   
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Figure 1.6 – General reaction mechanism of a DNA glycosylase with β-lyase activity. 
Structure c is the β-elimination product. 
 
 
 
Cells have a variety of genes that encode for DNA glycosylases that repair 
specific oxidative damage to the nucleobases.  8-oxoG is a major product of a single 
electron oxidative event at a guanine residue24 and is formed frequently in cellular 
DNA.25  Therefore, cellular systems are well-equipped to deal with 8-oxoG formation.  
Table 1.3 outlines the various bacterial BER enzymes responsible for the removal of 8-
oxoG lesions and their mammalian homologues.  The bacterial glycosylases include 
MutM which excises 8-oxoG lesions formed within a DNA sequence40,41 and MutY 
which excises an adenine paired with an 8-oxoG residue42 which will occur following a 
round of replication.  MutT degrades 8-oxoGTP to the monophosphate before it can be 
incorporated into the genome.43  OGG1 is the mammalian glycosylase which is 
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homologous to the bacterial glycosylase MutM.44  8-oxoG was considered to be the major 
DNA base lesion caused by oxidative stress until just recently and OGG1 was considered 
to be the major repair enzyme for oxidative DNA damage in mammalian systems.  
Studies conducted with OGG1 deficient mice have shown that 8-oxoG lesions accumulate 
in genomic DNA at a rate of nearly 10-100 fold as compared to OGG1 proficient 
mice.45,46  Despite the fact that such high levels of 8-oxoG were observed to accumulate 
in OGG1 deficient mice, the spontaneous mutation rate in those mice was relatively low 
and no tumor formation was detected.45  However, there are many oxidants that are 
known to induce tumor formation so based on studies conducted with OGG1 deficient 
mice, it can be reasoned that 8-oxoG is not likely the major oxidative base lesion leading 
to cancer initiation in cells exposed to oxidants.  Further oxidative nucleobase lesions 
produce higher mutation rates than 8-oxoG33-35 and therefore have the potential to play a 
more significant role in cancer initiation than 8-oxoG.           
 
 
Table 1.3 – BER glycosylases known to repair Cr(VI) induced nucleobase lesions.47  
Some of these glycosylases are known to repair additional lesions not listed here but those 
additional lesions are not associated with Cr(VI) induced genetic damage.  
 
BER Glycosylase Nucleobase Lesion Substrates Mammalian Homolog 
MutM (Fpg) 8oxoG:C, Sp:C, Gh:C, 8oxoG:G, Sp:G, 
Gh:G 
OGG1 
MutY 8oxoG:A, G:A MYH 
MutT 8oxo dGTP, 8oxo dATP NTH1 
Nei Sp:A, Gh:A, 8oxoG:C, Sp:C, Gh:C, 
8oxoG:G, Sp:G, Gh:G 
NEIL1, NEIL2, NEIL3 
 
 
 
With the discovery of further oxidized DNA lesions such as Sp came the 
discovery of DNA glycosylases that recognize and cleave those further oxidized DNA 
lesions.  Endonuclease VIII (Nei) is a bacterial glycosylase that has been shown to repair 
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further oxidized DNA lesions including Sp.48,49  Nei deficient E. coli have been shown to 
accumulate Sp lesions but not 8-oxoG lesions following chromate exposure (Figure 
1.7).31  This indicated that the Nei repair enzyme is directed specifically at further 
oxidized lesions. Recently, three mammalian homologues of the Nei gene were identified 
and labeled Neil1, Neil2, and Neil3 (Nei-Like).50,51  NEIL1 and NEIL2 have been shown 
to recognize the further oxidized DNA lesion Sp and NEIL1 was shown to cleave Sp in 
both single and double stranded oligonucleotides.49  We expected that NEIL1 deficient 
mammalian cells would accumulate Sp lesions and be less resistant to Cr(VI) as was 
observed in the Nei deficient E. coli studies.  However, as this thesis will demonstrate, 
NEIL1 plays a much more complex role in mammalian cells that just BER creating a 
different outcome than initially hypothesized. 
 
 
 
Figure 1.7 – Sp accumulation in Nei deficient E.  coli over their wild type counterpart but 
not in MutM/MutY deficient E. coli over their wild type counterpart. Taken from [31]. 
 
 
 
 
 
 12
References 
 
1. Newman, D. (1890) A Case of Adeno-carcinoma of the Left Inferior Turbinated 
Body, and Perforation of the Nasal Septum, in the Person of a Worker in Chrome 
Pigments. Glasgow Medical Journal 33, 469-70. 
  
2.    Baetjer, A.M. (1950) Pulmonary carcinoma in chromate workers II. Incidence on 
basis of hospital records.  Arch. Indust. Hyg. Occup. Med. 2, 505-516. 
 
3.    Bidstrup, P.L. (1951) Carcinoma of the lung in chromate workers.  Br. J. Ind. Med. 
8, 302-305. 
 
4.    Bidstrup, P.L., Case, R.A.M. (1956) Carcinoma in the lung of workmen in the 
bichromate-producing industry in Great Britain.  Br. J. Ind. Med. 13, 260-264. 
 
5.    Pfeil, R. (1935) Lungentumoren als Berufskrankung in Chromatbetrieben.  Dtsch. 
Med. Wochensch 61, 1197-1202. 
 
6. Stern, R.M. (1982) Chromium compounds: production and occupational exposure. 
In: Langard, S. ed. Biological and Environmental Aspects of  Chromium. Elsevier 
Biomedical Press, 5-47. 
 
7.    Katz, S.A., Salem, H. (1994) The biological and environmental chemistry of 
chromium. VCH Publishers: New York, 5. 
 
8.    Toxicological Review of Hexavalent Chromium, U.S. Environmental Protection 
Agency, Washington, DC, 1998. 
 
9.    Spiccia, L., Marty, W. (1986) Fate of active chromium hydroxide Cr(OH)3-3H2O, in 
aqueous suspension.  A study of chemical changes involving aging.  Inorg. Chem. 
25, 266-271. 
 
 13
10.  National Priorities List Basic Site Query Results.  9 Nov. 2006.  U.S. Evironmental 
Protection Agency.  9 Nov. 2006. <oaspub.epa.gov/oerrpage/basicqry>.   
 
11.  Consumer Factsheet on: Chromium.  21 Feb. 2006.  EPA Ground Water and 
Drinking Water.  9 Nov. 2006. <www.epa.gov/safewater/contaminants/ 
dw_contamfs/chromium.html>. 
 
12.  Corporate-Wide Settlement Agreements.  25 Oct. 2006.  Occupational Safety and 
Health Administration.  9 Nov. 2006. <www.osha.gov/pls/oshaweb/owadisp. 
show_document?p_table=CWSA&p_id=883>. 
 
13. O’Brien, T.J., Ceryak, S., Patierno, S.R. (2003) Complexities of chromium 
carcinogenesis: role of cellular response, repair and recovery mechanisms. Mut. Res. 
533, 3-36. 
 
14. Arslan, P., Beltrame, M., Tomasi, A. (1987) Intracellular chromium reduction. 
Biochim. Biophys. Acta. 931, 10-15. 
 
15.   Kortenkamp, A., Beyersmann, D., O’Brien, P. (1987) Uptake of chromium (III) 
complexes by erythrocytes.  Toxicol. Environ. Chem. 14, 23-32. 
 
16.   Standeven AM, Wetterhahn KE. (1991) Ascorbate is the principle reductant of 
 chromium(VI) in rat liver and kidney ultrafiltrates. Carcinogenesis 12, 1733-1737. 
 
17.   Taspakos, M.J., Wetterhahn, K.E. (1983) The interaction of chromium with  nucleic 
acids. Chem. Biol. Interact. 46, 265-277. 
 
18.   Bose, R.N., Fonkeng, B.S., Moghaddas, S., Stroup, D. (1998) Mechanisms of DNA 
damage by chromium(V)-DNA carcinogens. Nucleic Acids Res. 26, 1588-1596.  
 
 
 14
19. Burrows, C.J., Muller, J.G. (1998) Oxidative nucleobase modifications leading to 
strand scission. Chem. Rev. 98, 1109-1151. 
 
20. Tsou, T.C., Yang, J.L. (1996) Formation of reactive oxygen species and DNA 
strand breakage during interaction of chromium(III) and hydrogen peroxide in vitro: 
evidence for a chromium(III)-mediated Fenton-like reaction. Chem. Biol. Interact. 
102, 133-153. 
 
21. Aiyar, J., Berkovits, H.J., Floyd, R.A., Wetterhahn, K.E. (1990) Reaction of 
chromium(VI) with hydrogen peroxide in the presence of glutathione: reactive 
intermediates and resulting DNA damage. Chem. Res. Toxicol. 3, 595-603. 
 
22. Aiyar, J., Berkovits, H.J., Floyd, R.A., Wetterhahn, K.E. (1991) Reaction of 
chromium(VI) with glutathione or with hydrogen peroxide: identification of 
reactive  intermediates and their role in chromium(VI)-induced DNA damage. 
Environ. Health Perspect. 92, 53-62. 
 
23. Mueller, S., Riedel, H.D., Stremmel, W. (1997) Determination of catalase activity at 
physiological hydrogen peroxide concentrations. Anal. Biochem. 245, 55-60. 
 
24. Steenken, S., Jovanovic, S. (1997) How easily oxidizable is DNA?  One-electron 
reduction potentials of adenosine and guanosine radicals in aqueous solution.  J. 
Am. Chem. Soc. 119, 617-618. 
 
25. ESCODD (2002) Comparative analysis of baseline 8-oxo-7,8-duhydroguanine in 
mammalian cell DNA, by different methods in different laboratories: an approach to 
consensus. Carcinogenesis 23, 2129-2133.  
 
26. Steenken, S., Jovanovic, S.V., Bietti, M., Bernhard, K. (2000) The trap depth (in 
DNA) of 8-oxo-7,8-dihydro-2’deoxyguanosine as derived from electron-transfer 
equilibria in aqueous solution. J. Am. Chem. Soc. 122, 2373-2374. 
 15
27. Saito, I., Takayama, M., Sugiyama, H., Nakatani, K. (1995) Photoinduced DNA 
cleavage via electron transfer: demonstration that guanine residues located 5’ to 
guanine are the most electron-donating sites.  J. Am. Chem. Soc. 117, 6406-6407.  
 
28. Helbock, H.J., Beckman, K.B., Ames, B.N. (1999) 8-hydroxydeoxyguanosine and 
8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol. 
300, 155-156.  
 
29. Shibutani, S., Takeshita, A., Grollman, A.P. (1991) Insertion of specific bases 
during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349, 431-
434. 
 
30. Luo, W., Muller, J.G., Rachlin, E.M., Burrows, C.J. (2000) Characterization of 
spiroiminodihydantoin as a product of one electron oxidation of 8-oxo-7,8-
dihydroguanosine.  Org. Lett. 2, 613-616. 
 
31. Hailer, M.K., Slade, P.G., Martin, B.D., Sugden, K.D. (2005) Nei deficient 
Escherichia coli are sensitive to chromate and accumulate the oxidized guanine 
lesion spiroiminodihydantoin. Chem. Res. Toxicol. 18, 1378-1383.  
 
32. Delaney, S., Barton, J.K. (2003) Long range DNA charge transport. J. Org. Chem. 
68, 6475-6483. 
 
33.   Duarte, V., Muller, J.G., Burrows, C.J. (1999) Insertion of dGMP and dAMP during 
in vitro DNA synthesis opposite an oxidized form of 7,8-dihydro-8-oxoguanine. 
Nucleic Acids Res. 27, 496-502. 
 
34.   Henderson, P.T., Delaney, J.C., Muller, J.G., Neeley, W.L., Tannenbaum, S.R., 
Burrows, C.J., Essigmann, J.M. (2003) The hydantoin lesions formed from 
oxidation of 7,8-dihydro-8-oxoguanine are potent sources of replication errors in 
vivo. Biochemistry 42, 9257-9262. 
 16
35.   Kornyushyna, O., Berges, A.M., Muller, J.G., Burrows, C.J. (2002) In vitro 
nucleotide misinsertion opposite the oxidized guanosine lesions 
spiroiminodihydantoin and guanidinohydantoin and DNA synthesis past the lesions 
using Escherichia coli DNA polymerase I (Klenow fragment). Biochemistry 41, 
15304-15314. 
 
36.   David, S.S., Williams, S.D. (1998) Chemistry of glycosylases and endonucleases 
involved in base-excision repair. Chem. Rev. 98, 1221-1261. 
 
37.   Lewin, B. (2004) Genes VIII. Pearson Education, Inc. Upper Saddle River, NJ. pp. 
447-452. 
 
38. Sancar, A., Lindsey-Boltz, L.A., Ünsal-Kaçmaz, K., Linn, S. (2004) Molecular 
mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. 
Rev. Biochem. 73, 39-85. 
 
39. McCullough, A.K., Dodson, M.L., Llyod, R.S. (1999) Initiation of base excision 
repair: glycosylase mechanisms and structures. Annu. Rev. Biochem. 68, 255-85. 
 
40. Chung, M.H., Kasai, H., Jones, D.S., Inoue, H., Ishikawa, H., Ohtsuka, E., 
Nishimura, S. (1991) An endonuclease activity of Excherichia coli that specifically 
removes 8-hydroxy-guanine residues from DNA. Mut. Res. 254, 1-12.  
 
41. Tchou, J., Kasai, H., Shibutani, S., Chung, M.H., Laval, J., Grollman, A.P., 
Nishimura, S. (1991) 8-oxogunaine (8-hydroxyguanine) DNA glycosylase and its 
substrate specificity. Proc. Natl. Acad. Sci. USA 88, 4690-4694. 
 
42. Michaels, M.L., Cruz, C., Grollman, A.P., Miller, J.H. (1992) Evidence that MutY 
and MutM combine to prevent mutations by an oxidatively damaged form of 
guanine in DNA. Proc. Natl. Acad. Sci. USA 89, 7022-7025. 
 
 17
43. Tajiri, T., Maki, H., Sekiguchi, M. (1995) Functional cooperation of MutT, MutM, 
and MutY proteins in preventing mutations by spontaneous oxidation of guanine 
nucleotide in Escherichia coli. Mut. Res. 336, 257-267. 
 
44. Aburantani, H., Hippou, Y., Ishida, T., Takashima, R., Matsuba, C., Kodama, M.T., 
Yasui, A., Yamamoto, K., Asano, M., Fukasawa, K., Yoshinari, T., Inoue,  H., 
Ohtsuka, E., Nishimura, S. (1997) Cloning and characterization of mammalian 8-
hydroxyguanine-specific DNA glycosylase/apurinic, apyrimidinic lyase, a 
functional mutM homologue.  Cancer Res. 57, 2151-2156. 
 
45. Minowa, O., Arai, T., Hirano, M., Monden, Y., Nakai, S., Fukuda, M., Itoh, M., 
Takano, H., Hippou, Y., Abutantani, H., Masumura, K., Nohmi, T., Nishimura, S., 
Noda, T. (2000) Mmg/Ogg1 gene inactivation results in accumulation of 8-
hydroxyguanine in mice. Proc. Natl. Acad. Sci. USA 97, 4156-4161. 
 
46. Arai, T., Kelly, V.P., Minowa, O., Noda, T., Nishimura, S. (2002) High 
accumulation of oxidative DNA damage, 8-hydroxyguanine, in Mmh/Ogg1 
deficient mice by chronic oxidative stress. Carcinogenesis 23, 2005-2010. 
 
47. Hazra, T.K., Muller, J.G., Manuel, R.C., Burrows, C.J., Llyod, R.S., Mitra, S. 
(2001) Repair of hydantoins, one electron oxidation product of 8-oxoguanine, by 
DNA glycosylases of Escherichia coli. Nucleic Acids Research 29, 1967-1974.  
 
48. Jiang, D., Hatahet, Z., Melamede, R.J., Kow, Y.W., Wallace, S.S. (1997) 
Characterization of Escherichia coli endonuclease VIII. J. Biol. Chem. 272,  32230-
32239. 
 
49. Hailer, M.K., Slade, P.G., Martin, B.D., Rosenquist, T.A., Sugden, K.D. (2005) 
Recognition of the oxidized lesions spiroiminodihydantoin and guanidinohydantoin 
in DNA by the mammalian base excision repair glycosylases  NEIL1 and NEIL2. 
DNA Repair 4, 41-50. 
 18
50. Takao, M., Kanno, S., Kobayashi, K., Zhang, Q., Yonei, S., van der Horst, G., 
Yasui, A. A back-up glycosylase in Nth1 knock-out mice is a functional Nei 
(endonuclease VIII) homologue. J. Biol. Chem. 277, 42205-42213. 
 
51. Hazra, T.K., Kow, Y.W., Hatahet, Z., Imhoff, B., Boldogh, I., Mokkapati, S.K., 
Mitra, S., Izumi, T. (2002) Identification and characterization of a novel human 
DNA glycosylase for repair of cytosine derived lesions. J. Biol. Chem. 277, 30417-
30420.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19
CHAPTER 2 
Characterization of a NEIL1 Deficient Cell Line 
 
2.1 Introduction 
 
 The NEIL1 BER glycosylase was first described in the literature in 2002.1-4  The 
Neil1 gene maps to the 15q22 chromosome location in humans.5  Deletions in the 15q 
chromosome arm are observed in more than 70% of human small cell lung carcinomas.5  
Substrates for NEIL1 include DNA base lesions such as formamido-pyrimidines (FapyG 
and FapyA), thymine glycol, and 5-hydroxyuracil.1-3,6  These lesions are associated with 
oxidative base damage so it was thought that NEIL1 may also be capable of cleaving 
some of the oxidative base lesions which form following exposure of DNA to chromate.  
Of particular interest were the hydantoin lesions as they had previously been shown to 
form directly from 8-oxoG lesions in synthetic oligonucleotide systems exposed to single 
electron oxidants.7-9,16  The specific activity of NEIL1 and NEIL2 in excising 
spiroiminodihydantoin (Sp), guanidinohydantoin (Gh), and 8-oxoG lesions has been 
studied using purified NEIL1 and NEIL2 enzymes.10  These studies have shown that 
NEIL1 but not NEIL2 will cleave Sp lesions from duplex DNA (Figure 2.1a).10  NEIL2 
was capable of cleaving Sp from single-stranded oligonucleotides and could recognize but 
not cleave Sp in duplex DNA (Figure 2.1b).10  Both enzymes showed little or no affinity 
for the 8-oxoG lesion.10   
 The NEIL glycosylases harbor intrinsic lyase activity that allows them to complete 
βδ-elimnation (Figure 2.2) at an apurinic/apyrimidinic (AP) site unlike OGG1.11  OGG1 
also possesses intrinsic lyase activity that would allow it to carry out β-elimination at an 
AP site following glycosidic bond cleavage.12  However, this lyase activity is weak and 
OGG1 is typically out competed for the AP site by apurinic/apyrimidinic endonuclease 
(APE).11  The βδ-elimnation product formed by further processing of the AP site by 
NEIL1 or NEIL2 has both a 5' and 3' phosphate termini.13  APE will not recognize a free 
3' phosphate suggesting that the NEIL1 and NEIL2 cleavage products must be processed 
differently than through the typical APE-dependent pathway.  In fact, it has been shown 
that the 3' phosphate can be removed by DNA 5'-kinase/3'-phosphatase – polynucleotide 
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kinase (PNK)14 - providing the alternative pathway needed to complete processing of the 
damaged site prior to reinsertion of a new base by a DNA polymerase. 
 
 
 
 
Figure 2.1a – The NEIL1 glycosylase cleaves Sp paired with any of the four natural 
DNA bases.  A δ-elimination product was observed in a duplex DNA system. Taken from 
[10]. 
 
 
 
 
 
Figure 2.1b – The NEIL2 glycosylase is unable to cleave the Sp lesion in duplex DNA 
regardless of which natural DNA base it is paired. Taken from [10]. 
 
 
 
 Armed with the knowledge that NEIL1 and NEIL2 are capable of cleaving 
secondary oxidative lesions from chromate damaged DNA, a system was developed to 
monitor intracellular lesion accumulation.  OGG1 is the mammalian homolog of MutM 
and NEIL1 and NEIL2 are mammalian homologues of Nei.  A MutM-/MutY- double 
knock-out and Nei deficient E. coli cell lines were exposed to chromate and their DNA 
was monitored for accumulation of 8-oxoG and Sp lesions.15  The Nei deficient cell line 
was shown to have elevated sensitivity to chromate and to accumulate Sp lesions but not 
8-oxoG lesions as was observed in the MutM-/MutY- double knock-out.15   
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Figure 2.2 – βδ-elimination scheme that is carried out by the NEIL1 and NEIL2 
glycosylases.13 
 
 
 
 
 A Neil1-/- mouse was engineered using a null-gene knock out plasmid which was 
inserted into the Neil1-coding region.16  The Neil1-/- mice developed a number of 
metabolically related problems including obesity, fatty liver disease, kidney 
vacuolization, hyperleptinemia, hyperinsulinemia and increased mitochondrial DNA 
damage.16  All of these conditions can be linked to genetic damage initiated by reactive 
oxygen species (ROS) and therefore indicated that cells from a Neil1-/- mouse line should 
be more sensitive to oxidative stress than their wild type counterparts.  Kidney epithelial 
cells from both the wild type and Neil1-/- mouse lines have been generously donated 
allowing us to analyze the effects of chromate exposure in a NEIL1 deficient mammalian 
system.  
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 To begin our studies with the NEIL1 cell lines, we first analyzed the cells for the 
presence or absence of an uninterrupted Neil1 gene and then for their ability to excise 8-
oxoG and Sp lesions from duplex DNA.  We expected to observe cleavage of the 8-oxoG 
lesion by both the wild type and Neil1-/- cell lines as the mOGG1 gene was unmodified in 
both cell lines.  Without the presence of a functional Neil1 gene however, we predicted 
that the Neil1-/- cell line would be unable to cleave Sp lesions.  Our results however 
demonstrated that Sp can still be cleaved by cellular extracts devoid of functional NEIL1 
enzyme indicating that NEIL1 may not be solely responsible for excision of Sp lesions in 
a cellular environment. 
 
2.2 Materials and Methods 
 
 2.2.1 Murine Cell Growth Conditions Neil1+/+, Neil1+/-, and Neil1-/- murine 
kidney epithelial cells were obtained from Dr. Steven Llyod at the Oregon Health and 
Science University (Portland, OR).  All three cell lines were grown in DMEM containing 
4.5 g/L D-glucose, L-glutamine, and 110 mg/L sodium pyruvate (Gibco) which was 
supplemented with 15% fetal calf serum (HyClone) and 1% 100X antibiotic-antimycotic 
(Gibco).  Cells were maintained at 37o C under an atmosphere of 5% CO2 to maintain a 
constant pH. 
   
 2.2.2 DNA Extraction Media was removed and discarded from flasks in 
which cells had formed a complete monolayer.  The cells were rinsed with 1X PBS 
(Sigma) and harvested by treatment with Trypsin-EDTA (Gibco).  The cell samples were 
pelleted at 300 x g and the supernatant was discarded.  Samples were placed in 15 mL 
conical tubes which were placed on ice followed by the addition of 1 mL of 4o C DNA 
extraction buffer (0.1 M Tris-HCl, 0.1 M NH4Cl, pH 8.0) to each sample.  Cell pellets 
were mixed thoroughly but gently and then sonicated for 5 min. in a Branson 3200 
sonicating water bath.  Cell samples were pelleted at 2400 x g (4o C) for 5 min. and the 
supernatant was discarded.  Pellets were resuspended in 300 µL of DNA extraction buffer 
containing 33 U of RNAse T1 (Sigma) and 200 µg of RNAse A (Sigma).  After 1 hour of 
incubation at 37o C, 300 µL of DNA extraction buffer containing 300 µg of Proteinase K 
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(Invitrogen) and 1% SDS (Gibco) was added.  The samples were again mixed thoroughly 
but gently and allowed to incubate for an additional 1 hour at 37o C.  750 µL of 
concentrated, buffered phenol (pH 7.9, Sigma) was then added and each sample was 
thoroughly mixed before being centrifuged at 2400 x g for 5 min.  The top layer was 
removed and placed into a fresh 1.5 mL tube, mixed with 250 µL of a 25:24:1 phenol : 
chloroform : isoamyl alcohol solution (pH 7.9, EMD), and centrifuged at 12000 x g for 5 
min.  Again the top layer was removed and placed into a fresh 1.5 mL tube, mixed with 
250 µL of a 24:1 chloroform : isoamyl alcohol solution (Sigma), and centrifuged at 12000 
x g for 5 min.  The top layer was mixed with 30 µL of 10 M ammonium acetate (pH 5.0) 
and 1 mL of -20o C 100% ethanol in a fresh 1.5 mL tube.  Samples were mixed and 
allowed to precipitate at -20o C overnight before being pelleted at 12000 x g (4o C) for 15 
min.  The supernatant was discarded, the pellet was washed with 1 mL of 70% ethanol, 
and re-centrifuged at 12000 x g (4o C) for 10 min.  Residual ethanol was dried and the 
pellet was resuspended in 100 µl of deionized water.  Absorbance at 260 nm (OD260) was 
obtained in order to determine the DNA content of each sample.  
 
 2.2.3 Genotyping NEIL1 Cell Lines A PCR reaction was run for a DNA 
sample from each cell line using the same forward Neil1 primer and a two different 
reverse primers specific for either the wild type Neil1 gene or the interrupted form.  The 
forward primer used for both genotypes was derived from Neil1 intron 1 to Neil1 exon 2, 
5'-CAC CAG TGA GCA AGA CAG CCA T-3'.  A reverse primer for the Neil1+/+ 
genotype was developed from codons 6-12 in the Neil1 gene which were interrupted in 
the Neil1-/- genotype, 5'-GTG GCT GGC CAG GTG CAG CTC-3'.  A reverse primer for 
the Neil1-/- genotype was developed from the neomycin open reading frame (ORF) that 
was used to interrupt the Neil1 gene, 5'-CCA GCT CAT TCC TCC CAC TCA-3' (Figure 
2.3a).  Template DNA (500 ng) was reacted with 2.5 U of Taq DNA polymerase 
(Novagen) in a solution of 16 nM forward Neil1 primer (Integrated DNA Technologies), 
0.2 mM dNTP mixture (New England Biolabs), 1.5 mM MgCl2 buffer (Novagen), and 16 
nM of either the wild type or knock-out Neil1 reverse primer (Integrated DNA 
Technologies).  The reaction underwent 35 rounds of PCR amplification in a PTC-200 
Peltier Thermocycler.  Amplified DNA samples were loaded onto a 1.2% agarose gel 
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containing 0.5 µg/mL ethidium bromide.  Samples were loaded in a 30% glycerol buffer 
supplemented with 0.25% xylene cyanol (Sigma) and 0.25% bromophenol blue (Aldrich).  
The gel was run in a Tris-Borate buffer (0.045M Tris-Base, 0.045 M Borate, 0.001 M 
EDTA) at 90 V for 1.5 hours.  PCR product bands were visualized using a Fujifilm FLA-
3000 phosphoimager. 
 
 2.2.4 Sp Oligonucleotide Synthesis A 22 base pair (bp) oligonucleotide 
containing a single 8-oxoG lesion (5'-ACC AGC AGC 8-oxoGGC CGC ACC AGT G-3') 
was purchased from TriLink Biotech.  This oligonucleotide was oxidized using Cr(V) – 
Salen which was synthesized by reacting Cr(III) – Salen with iodosylbenzene in a 1:2 
molar ratio respectively in dry acetonitrile for 15 min. at room temperature.17  Each 
oxidation reaction consisted of 0.1 mM 8-oxoG oligonucleotide, 10 mM phosphate buffer 
at pH 7.4, and 0.8 mM Cr(V) – Salen.  The reaction was allowed to proceed for 40 min. at 
37o C.  Upon completion of the reaction, the resulting Sp oligonucleotide was isolated on 
a Dionex NucleoPac PA-100 4 mm x 250 mm anion exchange column.  A linear gradient 
was employed over 18 minutes from 90% mobile phase A (10% aqueous acetonitrile) and 
10% mobile phase B (1.5 M ammonium acetate, pH 6.0 in 10% aqueous acetonitrile) to 
100% mobile phase B.  Sp containing oligonucleotide fractions were collected, combined 
and concentrated.      
 
 2.2.5 32 P Labeling and Annealing of Oligonucleotides  
Oligonucleotide concentrations were obtained by measuring an OD260 for the synthesized 
Sp oligonucleotide and the 8-oxoG oligonucleotide.  A control oligonucleotide with a 
normal guanine residue present in place of the 8-oxoG lesion and a complement 
oligonucleotide were purchased from Integrated DNA Technologies and the concentration 
of each was determined in the same way.  Equivalent molar concentrations of the Sp, 8-
oxoG, and control oligonucleotides were 5' labeled with 32P-γ-ATP (GE Health Care).  
Each reaction consisted of 10 U of polynucleotide kinase (Promega) 10 µCi 32P-γ-ATP 
and 1X polynucleotide kinase buffer (Promega).  Excess 32P-γ-ATP was removed using a 
P6 Micro Bio-Spin Chromatography Column from BioRad.  A 20% excess of the 
complement oligonucleotide was added to each of the three labeled oligonucleotide 
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solutions.  These were then annealed by heating to 95o C for 5 min. before being cooled 
slowly (~1o C/5 min.) to room temperature.  Once annealed, the solutions were stored at 
4o C and used as a stock solution for up to a week.   
 
 2.2.6 Nuclear Extract Preparation Both NEIL1 deficient and wild type 
epithelial cells were harvested by gently scraping them from 75 cm2 flasks with a cell 
scraper after being rinsed with ice cold 1X PBS containing phosphatase inhibitors.  
Nuclear extracts were then isolated using the Nuclear Extract Kit from Active Motif.  A 
20 µL aliquot of nuclear extracts from each cell line was retained to determine protein 
concentrations.  The Bicinchoninic Acid Protein Assay Reagent Kit (Pierce) was used to 
determine protein concentrations.  The remainder of the nuclear extracts were stored at     
-80o C in 25 µL aliquots.      
 
 2.2.7 Sp Cleavage Assay Nuclear extracts were thawed immediately prior to 
use in the cleavage assay.  Reaction buffer for the cleavage assay was composed of 20 
mM Tris-HCl (GibcoBRL) pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA, 
Sigma), 1 mM Dithiothreitol (DTT, Fisher), and 100 µg/mL DNAse free Bovine Serum 
Albumin (New England Biolabs).  500 nM concentrations of each annealed 
oligonucleotide were reacted with 40 µg of nuclear extracts at 37o C.  500 nM 
concentrations of each annealed oligonucleotide were also reacted with 0.8 U of purified 
hOGG1 (New England Biolabs) as a control for 8-oxoG cleavage.  5 µL aliquots of the 
reaction solutions were removed at 0, 60, 90 and 120 min.  Each aliquot was immediately 
quenched by adding 5 µL of a formamide denaturing loading dye (1 mL formamide 
(Fisher), and 1 mg/mL bromophenol blue (Aldrich)) that had been preheated to 95o C.  
These were allowed to denature at 95o C for 5 min. and were then placed on ice for 3 min. 
immediately prior to being loaded onto a pre-poured 15% TBE, 7 M urea pre-poured gel 
(Invitrogen).  The gel was run in a Tris-Borate-EDTA buffer (45 mM Tris Base (Aldrich), 
45 mM Boric Acid (EMD Biosciences), and 0.001 M EDTA (Sigma)) for 40 min. at 180 
V.  Gels were visualized on a Fujifilm FLA-3000 phosphoimager. 
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2.3 Results 
 
 2.3.1 Genotype Analysis Primer sequences for the Neil1+/+ and the Neil1-/- 
genotypes were provided by Dr. Stephen Llyod (Figure 2.3a).  The expected PCR 
fragment lengths were 268 bp for the Neil1+/+ genotype, 448 bp for the Neil1-/- genotype 
and both a 268 bp fragment and a 448 bp fragment for the Neil1+/- genotype.  A 
representative gel is shown in figure 2.3b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3a – Neil1 gene showing primer locations in both the wild type and interrupted 
form of the gene.  The reverse primers are derived from exon 1.  Codons 6-12 make up 
the wild type reverse primer (A).  The knock out reverse primer is derived from the 
neomycin resistance gene that is inserted into the 5’ region of exon 1 in the Neil1-/- gene 
(B).  This insertion causes a 79 bp deletion from the 5’ end of exon 1 and includes the 
neomycin open reading frame (Neo) and a phosphoglycerate kinase promoter (PGK).16  
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Figure 2.3b –PCR products corresponding to the three murine kidney epithelial cell lines.  
Lanes 3-10 all include the forward Neil1 primer.  Lanes: 1 - molecular weight marker, 2 - 
empty, 3 - no template with Neil1+/+ reverse primer, 4 - no template with Neil1-/- reverse 
primer, 5 - Neil1+/+ template with Neil1+/+ reverse primer (268 bp product), 6 - Neil1+/+ 
template with Neil1-/- reverse primer, 7 - Neil1-/- template with Neil1+/+ reverse primer, 8 - 
Neil1-/- template with Neil1-/- reverse primer (448 bp product), 9 - Neil1+/- template with 
Neil1+/+ reverse primer (268 bp product), 10 - Neil1+/- template with Neil1-/- reverse 
primer (448 bp product). 
 
 
 2.3.2 Sp Cleavage Assay The original 8-oxoG 22-mer was purified on a 
Dionex NucleoPac PA-100 4 mm x 250 mm anion exchange column under the same 
separation conditions mentioned previously for the oxidized Sp 22-mer.  The 8-oxoG 22-
mer eluted after 11.7 min. (Figure 2.4a).  This peak was collected and concentrated before 
being oxidized with Cr(V) – Salen to form the Sp 22-mer.  Figure 2.4b is the HPLC trace 
from the product of the oxidized 8-oxoG 22-mer.  The oxidation reaction was not 
cleaned-up prior to separation by HPLC resulting in a significant peak at 1.3 min. 
representing residual reaction components in the buffer front.  Two small peaks with 
retention times of 9.8 and 10.2 min. represent a small amount of Gh/Ia 22-mer.  Residual 
8-oxoG 22-mer eluted at 11.5 min. while the two peaks representing the Sp 22-mer eluted 
at 13.1 and 13.5 min.  When synthesized in single-stranded DNA, Sp will form two 
isomers (Figure 2.4b).  The identity of these three sets of peaks has been confirmed in 
previous studies using ESI-MS analysis.18 
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  750 bp 
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  300 bp 
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 Purified hOGG1 enzyme, as well as 40 µg of nuclear extracts from both the 
Neil1+/+ and   Neil1-/- cell lines, were reacted with a control 22-mer, an 8-oxoG containing 
22-mer, and an Sp containing 22-mer.  The hOGG1 enzyme was unable to cleave the 
control substrate or the Sp substrate but showed very efficient cleavage of the 8-oxoG 
substrate (Figure 2.5-1).  Both the Neil1+/+ and Neil1-/- nuclear extracts were unable to 
cleave the control substrate but cleaved both the 8-oxoG and the Sp substrate (Figure 2.5-
2,3).  A single 12 bp product was observed in all of the reactions for which cleavage 
occurred.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4a – HPLC trace of the oligonucleotide containing a single 8-oxoG lesion.  
Retention time was 11.7 minutes.   
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Figure 2.4b – HPLC trace of the oligonucleotide containing a single 8-oxoG lesion after 
oxidation by Cr(V) – Salen.  Residual 8-oxoG 22-mer elutes at 11.5 minutes.  The two 
peaks that elute at 13.1 and 13.5 minutes represent the two 22-mer oligonucleotides 
containing each of the two Sp isomers.      
 
 
 
 
 
 
Figure 2.5 – Gel 1 shows the reaction between purified hOGG1 and a 22 bp substrate.  
Gel 1: a) lesion-free substrate, b) 8-oxoG substrate, c) Sp substrate.  Gel 2 shows the 
reaction between Neil1+/+ nuclear extracts and a 22 bp substrate. Gel 2: a) lesion-free 
substrate, b) 8-oxoG substrate, c) Sp substrate.  Gel 3 shows the reaction between Neil1-/- 
nuclear extracts and a 22 bp substrate.  Gel 3: a) lesion-free substrate, b) 8-oxoG 
substrate, c) Sp substrate.  Double bands in the substrate region occurred due to 
incomplete denaturation of oligonucleotides prior to electrophoretic separation.   
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2.4 Discussion  
  
 2.4.1 Genotype Confirmation The genotype of each of the kidney epithelial 
cell lines was confirmed upon receipt of the cells.  The Neil1+/+ cell line produced only a 
268 bp PCR amplified product confirming that it did indeed have two unaltered copies of 
the Neil1 gene.  The Neil1+/- cell line produced both a 268 bp and a 448 bp PCR amplified 
product indicating that it possessed one uninterrupted copy of the Neil1 gene and one 
interrupted Neil1 gene copy.  Finally, the Neil1 -/- cell line produced only the 448 bp PCR 
amplified product confirming that both copies of the Neil1 gene had been successfully 
interrupted with the neomycin open reading frame.  Many of our subsequent studies were 
conducted without use of the heterozygous cell line.   
   
 2.4.2 Sp Cleavage in a NEIL1 Deficient Cell Line A control reaction 
between a lesion-free DNA substrate and hOGG1 enzyme or the NEIL1 proficient and 
deficient nuclear extracts ensured that there was no spontaneous DNA cleavage occurring 
due to reaction conditions.  A second control reaction using the 8-oxoG DNA substrate 
showed that all three systems were able to excise the 8-oxoG lesion in duplex DNA.  This 
was the expected result as 8-oxoG is the primary target lesion for hOGG1 and because the 
mOGG1 gene was unaltered in both the wild type and Neil1-/- cell lines.  Based on studies 
conducted with purified NEIL1 enzyme showing that only NEIL1 and not NEIL2 could 
excise Sp lesions in duplex DNA, we hypothesized that a NEIL1 deficient cell line may 
not be capable of cleaving Sp lesions from duplex DNA.  Our results, however, 
demonstrated that the NEIL1 deficient as well as the NEIL1 proficient nuclear extracts 
were able to cleave the Sp lesion from duplex DNA.  The signal intensity of the cleaved 
12 bp Sp product looks similar between Gel 2 and 3 in figure 2.5.  However, the intensity 
of the 12 bp Sp product relative to that of the 12 bp 8-oxoG product on Gel 3 is much 
lower than that of the same comparison made on Gel 2.  This indicates that while the 
NEIL1 deficient nuclear extracts may be cleaving the Sp lesion, they are not cleaving Sp 
as efficiently as the NEIL1 proficient nuclear extracts.  There are several possible 
explanations for the Sp cleavage seen in the NEIL1 deficient nuclear extract reactions.  It 
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is likely that all three of the following explanations contribute to this observed Sp 
cleavage. 
 First, there may be a small amount of 8-oxoG substrate present in the Sp substrate 
lane.  It is possible that the shoulder on the 8-oxoG 22-mer peak runs into the Sp peaks as 
they are separated by HPLC (Figure 2.4b).  This proposal is based on the fact that in some 
of the cleavage gels, a faint 12 bp product band was visible in the Sp substrate lane for the 
purified hOGG1 reaction.  While some OGG1 homologues such as yeast OGG1 and 
OGG2 are capable of cleaving the Sp lesion in duplex DNA, the human form – hOGG1 – 
does not recognize the Sp lesion19 and hOGG1 is unable to excise Sp from duplex DNA 
paired with any of the four natural bases.18   This fact suggests it is unlikely that the faint 
cleavage product seen in the Sp substrate lane for the hOGG1 reaction is actually a 12 bp 
DNA fragment containing the Sp lesion.  There is also a small possibility that there may 
be some Gh/Ia substrate present as well.  This is much more unlikely than having 8-oxoG 
substrate contamination as the Gh/Ia substrate elutes prior to both the 8-oxoG and Sp 
substrate when separated by HPLC (Figure 2.4b).  This type of contamination, however, 
would not account for the faint cleavage product observed in the Sp substrate lane for the 
hOGG1 reaction as hOGG1 also has little or no affinity for the Gh/Ia lesion in duplex 
DNA.18  Thus, it is most likely that the small amount of product observed in the hOGG1 
reaction with the Sp substrate is a small amount of 8-oxoG substrate contaminating that 
reaction lane.  The amount of cleavage product observed in the NEIL1 deficient nuclear 
extract reaction with the Sp substrate was much more extensive than that observed for the 
hOGG1 reaction with that same substrate based on relative product intensities.  This 
indicates that 8-oxoG substrate contamination does not account for all of the observed Sp 
cleavage by the NEIL1 deficient nuclear extracts.  
 Secondly, the NEIL2 enzyme may be capable of excising the Sp lesion in vivo.  
NEIL2 was not capable of excising Sp from duplex DNA,10  however, purified NEIL2 
was capable of excising Sp from a single-stranded oligonucleotide and was able to 
recognize the Sp lesion in duplex DNA as demonstrated by a protein trapping assay.10  It 
is reasonable to then suggest that the NEIL2 enzyme may be capable of excising the Sp 
lesion when functioning in a complete cellular system probably by recruiting downstream 
proteins of the BER apparatus.  Unlike the in vitro NEIL1 and NEIL2 cleavage set-up, the 
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nuclear extracts used in our cleavage assay contain a wide variety of proteins capable of 
aiding in the BER process.  For example, the OGG1 enzyme has the ability to carry out β-
elimination at an AP site but it is much less efficient at this step than APE1.20,21  
Therefore, in a cellular system, OGG1 will be displaced by APE1 which will then remove 
the sugar residue preparing the AP site for insertion of a new base.20  Not much is yet 
know about NEIL1 and NEIL2 enzymatic functioning in a whole cell environment but it 
is likely that there are a variety of cellular proteins (for example DNA 5'-kinase/3'-
phosphatase) that may be able to assist NEIL1 and/or NEIL2 making it possible for these 
BER enzymes to excise lesions in vivo that they are incapable of cleaving without the aid 
of accessory proteins.    
 Thirdly, Mismatch Repair (MMR) may also be playing a role in excising the Sp 
lesion in vivo.  Typically MMR recognizes mismatched base pairs because they create a 
distortion in the DNA backbone.  This distortion is usually quite small as it just involves a 
few misplaced hydrogen bonds between base pairs.  The 8-oxoG lesion is not repaired by 
MMR because it does not create enough of a distortion in the DNA backbone to be 
recognized by MMR proteins as it simply shifts the N7 from a hydrogen bond acceptor to 
a hydrogen bond donor position.  The Sp lesion however, may be able to recruit both BER 
and MMR proteins.  Sp is small enough for BER enzymes to recognize and cleave it from 
duplex DNA.  However, unlike 8-oxoG, Sp creates a more significant distortion in the 
DNA backbone (Figure 2.6) since Sp does not maintain a planar conformation like the 
natural DNA bases and 8-oxoG.  This distortion is similar in magnitude to that seen with 
ternary Cr-DNA adducts and MMR has been shown to recognize DNA bending caused by 
ternary Cr-DNA adducts22 which do not create a large enough distortion to recruit 
Nucleotide Excision Repair (NER) proteins but are too bulky for BER enzymes.  Sp is 
probably not so bulky as to cause a DNA helix distortion large enough to recruit NER 
proteins but it may be enough of a distortion to recruit MMR proteins in addition to BER 
enzymes.   
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Figure 2.6 – The spiroiminodihydantoin lesion is composed of two imidazole rings which 
sit at a 90o angle to one another distorting the π-stacking structure of normal B-form 
DNA.     
 
 
 
 
2.5 Conclusions 
  
 We were able to confirm that the NEIL1 deficient cell line did not carry a  
functional copy of the Neil1 gene.  Based on that finding and the results of studies carried 
out with purified NEIL1 and NEIL2 glycosylases, we anticipated that the NEIL1 deficient 
murine epithelial cells would be unable to excise the Sp lesion from duplex DNA.  This 
did not turn out to be true although the efficiency of Sp excision from duplex DNA is 
reduced in the NEIL1 deficient cells as compared to their wild type counterpart.  
Therfore, we expected that the Neil1-/- cell line would be more sensitive to chromate than 
the Neil1+/+ cell line.  Since there was some Sp cleavage occurring in the Neil1-/- cell line, 
we did not expect that the difference in sensitivity to chromate would be as pronounced as 
that seen in Nei deficient E. coli.           
 
 
 
 
 34
References 
 
1. Morland, I., Rolseth, V., Luna, L, Rognes, T., Bjoras, M, Seeberg, E. (2002) 
 Human DNA glycosylases of the bacterial Fpg/MutM superfamily: an alternative 
 pathway for the repair of 8-oxoguanine and other oxidation products in DNA. 
 Nucleic Acids Res. 30, 4926-4936. 
 
2. Hazra, T.K., Izumi, T., Boldogh, I., Imhoff, B., Kow, Y.W., Jaruga, P., 
 Dizdaroglu, M., Mitra, S. (2002) Identification and characterization of a human 
 DNA glycosylase for repair of modified bases in oxidatively damaged DNA. 
 Proc. Natl. Acad. Sci. USA 99, 3523-3528. 
 
3. Bandaru, V., Sunkara, S., Wallace, S.S., Bond, J.P. (2002) A novel human DNA 
 glycosylase that removes oxidative DNA damage and is homologous to 
 Escherichia coli endonuclease VIII. DNA Repair 1, 517-529. 
 
4.   Takao, M., Kanno, S., Kobayashi, K., Zhang, Q., Yonei, S., van der Horst, G., 
 Yasui, A. A back-up glycosylase in Nth1 knock-out mice is a functional Nei 
 (endonuclease VIII) homologue. J. Biol. Chem. 277, 42205-42213. 
 
5. Stanton, S.E., Shin, S.W., Johnson, B.E., Meyerson, M. (2000) Recurrent allelic 
 deletion of chromosome arms 15q and 16q in human small cell lung carcinomas. 
 Genes Chromosomes Cancer 27, 323-331.  
 
6. Rosenquist, T.A., Zaika, E., Fernandes, A.S., Zharkov, D.O., Miller, H.,  
 Grollman, A.P. (2003) The novel DNA glycosylase NEIL1, protects mammalian 
 cells from radiation-mediated cell death. DNA Repair 2, 581-891. 
 
7. Duarte, V., Muller, J.G., Burrows, C.J. (1999) Insertion of dGMP and dAMP 
 during in vitro DNA synthesis opposite an oxidized form of 7,8-dihydro-8-
 oxoguanine. Nucleic Acids Res. 27, 496-502. 
 35
8. Luo, W., Muller, J.G., Rachlin, E.M., Burrows, C.J. (2000) Characterization of 
 spiroiminodihydantoin as a product of one-electron oxidation of 8-oxo-7,8-
 dihydroguanosine. Org. Lett. 2, 613-616. 
 
9. Luo, W., Muller, J.G., Rachlin, E.M., Burrows, C.J. (2001) Characterization of 
 hydantoin products from one-electron oxidation of 8-oxo-7,8-dihydroguanosine in 
 a nucleoside model. Chem. Res. Toxicol. 14, 927-938.  
 
10. Hailer, M.K., Slade, P.G., Martin, B.D., Rosenquist, T.A., Sugden, K.D. (2005) 
 Recognition of the oxidized lesions spiroiminodihydantoin and 
 guanidinohydantoin in DNA by the mammalian base excision repair glycosylases 
 NEIL1 and NEIL2. DNA Repair 4, 41-50. 
 
11. Mokkapati, S.K. Wiederhold, L., Hazra, T.K., Mitra, S. (2004) Stimulation of 
 DNA glycosylase activity of OGG1 by NEIL1:  functional collaboration between 
 two human DNA glycosylases. Biochemistry 43, 11596-11604. 
 
12. McCullough, A.K., Dodson, M.L., Llyod, R.S. (1999) Initiation of base excision 
 repair: glycosylase mechanisms and structures. Annu. Rev. Biochem. 68, 255-85. 
 
13.  Burrows, C.J., Muller, J.G. (1998) Oxidative nucleobase modifications leading to 
 strand scission. Chem. Rev. 98, 1109-1151. 
 
14. Wiederhold, L., Leppard, J.B., Kedar, P., Karimi-Busheri, F., Rasouli-Nia, A., 
 Weinfeld, M., Tomkinson, A., Izumi, T., Prasad, R., Wilson, S.H., Mitra, S.,  
 Hazra, T.K. (2004) AP-endonuclease-independent DNA base excision repair in  
 human cells. Mol. Cell 15, 209-220. 
 
15. Hailer, M.K., Slade, P.G., Martin, B.D., Sugden, K.D. (2005) Nei deficient 
 Escherichia coli are sensitive to chromate and accumulate the oxidized guanine 
 lesion spiroiminodihydantoin. Chem. Res. Toxicol. 18, 1378-1383. 
 36
16. Vartanian, V., Lowell, B., Minko, I.G., Wood, T.G., Ceci, J.D., George, S., 
 Ballinger, S.W., Corless, C.L., McCullough, A.K.,  Llyod, R.S. (2006) The 
 metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. 
 Proc. Natl. Acad. Sci. USA 103, 1864-1869. 
 
17. Srinivasan, K., Kochi, J.K. (1985) Synthesis and molecular structure of 
 oxochromium(V) cations. Inorg. Chem. 24, 4671-4675 
 
18. Sugden, K.D., Campo,K.C., Martin, B.D. (2001) Direct oxidation of guanine and 
 7,8-dihydro-8-oxoguanine in DNA by a high-valent chromium complex: a 
 possible mechanism for chromate genotoxicity. Chem. Res. Toxicol. 14, 1315-
 1322. 
 
19. Leipold, M.D., Workman, H., Muller, J.G., Burrows, C.J., David, S.S. (2003) 
 Recognition and removal of oxidized guanines in duplex DNA by the base 
 excision repair enzymes hOGG1, yOGG1, and yOGG2. Biochemistry 42, 11373-
 11381. 
 
20. Hill, J.W., Hazra, T.K., Izumi, T., Mitra, S. (2001) Stimulation of human 8-
 oxoguanine-DNA glycosylase by AP-endonuclease: potential coordination of the 
 initial steps in base excision repair. Nucleic Acids Res. 29, 430-438.   
 
21. Vidal, A.E., Hickson, I.D., Boiteux, S., Radicella, J.P. (2001) Mechanism of 
 stimulation of the DNA glycosylase activity of hOGG1 by the major human AP 
 endonuclease: bypass of the AP lyase activity step. Nucleic Acids Res. 29, 1285-
 1292. 
 
22. Strauss-Soukup JK, Vaghefi MM, Hogrefe RI, Maher III LJ. (1997) Effects of 
 neutralization pattern and stereochemistry on DNA bending by 
 methylphosphonate substitutions. Biochemistry 36, 8692-8698. 
 
 37
CHAPTER 3 
The Effects of a NEIL1 Deficiency on Chromate Sensitivity and Cell Cycle 
Regulation 
 
3.1 Introduction 
 
 The eukaryotic cell cycle is composed of four distinct phases - G1, S, G2, and M 
(Figure 3.1).  The G1 and G2 phases are growth periods for the cell.  During these phases, 
the overall mass of the cell will increase as the majority of cellular proteins are 
synthesized as well as organelles such as membranes, endoplasmic reticulum, 
mitochondria, and ribosomes.  Much of this growth prepares the cell to undergo a round 
of division since duplicates of most cellular components must be synthesized prior to 
replication.  Between the two growth phases is the S phase, or DNA synthesis phase.  It is 
at this time that all of the genomic DNA will be replicated.  The final stage of the cell 
cycle is mitosis (M phase) – cell division.  Mitosis is further broken down in to four 
segments; prophase, metaphase, anaphase, and telophase.  A rapidly replicating 
mammalian cell will complete one full cell cycle every 24 hours.1  Roughly 12 hours are 
spent in G1, 6 hours in S, 6 hours in G2, and 30 minutes in mitosis.1  
 The time spent in each phase of the cell cycle varies greatly between different 
types of cells in multicelluar organisms. A 24-hour cell cycle is common for skin cells or 
intestinal cells that are regenerated frequently.1  At the other extreme, neurons leave the 
cell cycle permanently so will never divide during their life time.  Neurons exit the cell 
cycle during the G1 phase and enter a sub-phase referred to as G0 (Figure 3.1).1  Other 
cells will also arrest at the G0 sub-phase but many can be stimulated to re-enter the main 
cell cycle, such as liver cells that only need to be regenerated about once per year or 
following damage to the liver tissue.  This type of arrest is normal for cells that do not 
need to replicate frequently.  Some cells may also enter an arrest phase during the G2 
period of growth as demonstrated by certain epidermal cells.1  Another reason that cells 
may enter a cell cycle arrest sub-phase, is due to the accumulation of DNA damage.  Four 
checkpoints throughout the cell cycle lead to temporary or permanent cell cycle arrest or 
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death.2  Three of these checkpoints are dedicated to monitoring DNA damage (Figure 
3.2).2   
 
 
 
 
 
Figure 3.1 – The eukaryotic cell cycle.  A growth period composed of the G1, S, and G2 
phases is collectively referred to as interphase.  Mitosis, or the phase of cell division, 
completes the cycle.  Cells can enter two arrest phases, G0 and G2 arrest as a way to 
temporarily or permanently exit the cell cycle.     
 
 
 
In the G1 phase, DNA is scanned to ensure that no damage was incurred during the 
previous round of mitosis and that one copy of each chromosome was distributed to the 
daughter nuclei.  However, the DNA may also be damaged during G1 by an exogenous 
factor such as chromate.  The cell can then enter the G0 arrest phase while any genetic 
damage is repaired.  If repair is successful, arrested cells can then re-enter the cell cycle 
and proceed into S phase.  Following S phase, the DNA will again be monitored for 
damage and to ensure that all DNA was properly replicated.  If there is damage, the cell 
will again be arrested but this time in the G2 arrest phase while the damage is repaired so 
that the cell can then progress into mitosis.   
G2 arrest phase 
G0 phase 
 39
 
 
 
 
 
 
 
   
 
 
Figure 3.2 – The cell cycle maintains checkpoints to monitor the integrity of DNA and 
other cell components.  If damage to cellular components is detected at these checkpoints, 
the cell will either go into arrest followed by entering a survival mode where the damage 
will be repaired or it will self-destruct via necrosis or apoptosis.   
 
 
 
 A cell is only capable of repairing so much genetic damage.  With a mutagen such 
as chromate, normal cells can survive following exposure to low concentrations of Cr(VI) 
since they are equipped to repair the oxidative DNA lesions that will be formed.  The 
cells should go into a period of arrest, repair the damage and then reenter the cell cycle.  
Exposure to very high concentrations of Cr(VI) may cause a cell to enter a necrotic 
pathway.  Necrosis is an unorganized form of cell death that will occur when a cell is 
Checkpoint for 
damaged DNA 
following division 
Checkpoint for 
DNA damage 
following synthesis 
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physically disrupted or incurs severe metabolic damage.3  This pathway can be viewed as 
a last resort as it can induce necrosis in many neighboring cells as well.  As a necrotic 
cells dies, its contents are rapidly released into the extracellular matrix and much of that 
material can be toxic when not compartmentalized within a cell.3  A third, and more 
common scenario is the apoptotic pathway.  When cells are exposed to intermediate but 
toxic concentrations of chromate, they can reach a point where they have too much DNA 
damage to be effectively repaired but have not been poisoned so badly that they will enter 
a necrotic pathway.  At what point the damage becomes so great that a cell will be 
diverted from a survival pathway into an apoptotic pathway is unknown.4  Instead, these 
cells will undergo cell degradation in a tightly regulated cascade of events collectively 
referred to as apoptosis.3   
 There are two apoptotic pathways, extrinsic and intrinsic.5  Both pathways are 
regulated by the action of caspases (cysteine proteases)5 and converge once the apoptotic 
cascade reaches the point of activation of the executioner caspases-2, 3, and 7.6,7  An 
internal signal such as DNA damage induced by Cr(VI), activates the intrinsic apoptotic 
pathway.5  The intrinsic pathway differs from the extrinsic in that the first signals for 
apoptosis are generated at the mitochondria rather than at the cell membrane.  p53, a 
tumor suppressor protein, monitors DNA for damage.8  Once that damage reaches a 
certain level, p53 will activate B-cell lymphoma 2 protein (Bcl-2) to form a dimer with 
Bcl-2 associated X protein (Bax).9-11  The Bax protein will travel to the mitochondria, 
associate with Bcl-2, insert itself into the outer membrane, and form a pore that allows 
cations to freely flow into the negatively charged intermembrane space of the 
mitochondria.3,12  This shift in voltage causes voltage-dependent anion channels (VDACs) 
present in the outer mitochondrial membrane to open allowing cytochrome c to escape 
into the cytoplasm.3,13  Cytochrome c will then bind to apoptotic protease activating factor 
1 (Apaf1) to cleave caspase 9.14  This cascade of events (Figure 3.3) activates numerous 
proteases and nucleases which will begin the orderly degradation of cellular proteins and 
DNA.   
 Apoptosis helps to protect cells exposed to chromate from accumulating mutations 
that could eventually lead to the initiation of cancer.  Based on the information obtained 
from the cleavage assays described in chapter 2, we hypothesized that a NEIL1        
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p53 Protein Detects Excessive DNA Damage
Bcl-2 + Bax Dimerize Forming Mitochondrial Membrane Pore
Cytochrome C Released Into Cytoplasm Through VDAC's
Cytochrome C and Apaf1 Bind and Cleave Caspase 9
Activated Caspase 9 Cleaves Caspases 2,3 and 7
Cellular Proteins and DNA Are Degraded
Intrinsic and Extrinsic Apoptotic
Pathways Meet Here
 
 
 
Figure 3.3 – The intrinsic apoptotic pathway.  The p53 protein detects excessive DNA 
damage and initiates a cascade of events that lead to release of cytochrome C from the 
mitochondria followed by activation of caspase 9.  Activated caspase 9 will then cleave 
and activate caspases 2,3, and 7 leading to the degradation of cellular proteins and DNA.  
The intrinsic and extrinsic pathways are initiated by different mechanisms but the two 
pathways join at the point where caspases 2,3, and 7 are activated. 
 
 
 
deficient murine epithelial cell line would accumulate more chromate-specific genetic 
damage and thus be more sensitive to chromate than a NEIL1 proficient murine epithelial 
cell line.  However, since the NEIL1 deficient cells were still capable of excising some 
chromate-induced Sp lesions from duplex DNA, we thought that the sensitivity difference 
between these two mammalian cell lines would not be as pronounced as had previously 
been observed in Nei deficient versus Nei proficient E. coli.15  Instead, the NEIL1 
deficient cell line was less sensitive to chromate than its wild type counterpart.  The only 
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difference between the two cell lines used in this study was the inactivation of a single 
BER glycosylase, NEIL1, and yet we found striking cell cycle progression differences 
between the two cell lines following exposure to chromate.  The NEIL1 deficient cell line 
also demonstrated apoptosis resistance.  As apoptosis resistance is a hallmark of cancer, 
this may provide evidence to explain why deletions in the 15q chromosome arm (the 
location of the Neil1 gene) are observed in more than 70% of human small cell lung 
carcinomas.16  This information taken together suggests that NEIL1, unlike other BER 
glycosylases including OGG1, plays a more dynamic role in maintaining control of the 
cell cycle engine than would be seen if this protein were solely involved in excising 
oxidized nucleobase lesions.        
 
3.2 Materials and Methods       
 
 3.2.1 Chromium Uptake Analysis Chromate-treated cells that had 
formed a complete monolayer were harvested as described previously using Trypsin-
EDTA and lyophylized prior to digestion.  For each freeze-dried sample, 1 mL of trace 
metal grade nitric acid (Fisher) was added and allowed to react for two hours.  This was 
followed by the addition of 200 uL of 30% hydrogen peroxide (J.T. Baker).  Samples 
were then allowed to digest for 48 hours uncovered in a ventilation hood.  Being careful 
not to disturb the salts which settled to the bottom of each tube, the liquid was transferred 
to a second 15 mL conical tube and brought up to a volume of 7 mL with nanopure water.  
Each sample was then analyzed for chromium content using an ICP-AES (IRIS Thermo 
Jarrell Ash). 
 
 3.2.2 Cell Quantification and Plating Neil1+/+, Neil1+/-, and Neil1-/- 
epithelial cells were harvested using Trypsin-EDTA.  Cells were placed in 15 mL conical 
tubes and pelleted at 300 x g.  Each sample was resuspended in 10 mL of complete media.  
A 20 µL aliquot of each cell suspension was placed on a hemocytometer for counting.  
Cell samples were then diluted to a final concentration of 10,000 cells/mL.  Once diluted, 
cells were distributed in 96-well plates (200 µL/well or 2,000 cells/well).     
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 3.2.3 Toxicity Assay Plated cells were allowed to grow for 48 hours at 
37o C and 5% CO2 before being treated with K2Cr2O7 (J.T. Baker).  Chromate solutions 
were made up as a 5X stock using filtered sterilized water.  Media was removed from the 
96-well plates.  Each stock solution was diluted to the final 1X concentration using 
complete media before being added to the 96-well plates.  The final concentrations of 
chromate used for the toxicity assay were 0, 1, 5, 10, 15, 20, 25, 30, 40, and 50 µM.    The 
plates were maintained for 24 hours under the conditions listed above. 
 Chromate solutions were removed and each plate was then rinsed with 1X 
phosphate buffered saline (PBS).  CellTiter-Blue (Promega) was mixed with complete 
media to form a 10% CellTiter-Blue solution.  200 µL of this solution was added to each 
well in the 96-well plate.  Plates were allowed to incubate in the CellTiter-Blue solution 
for 22 hours at which time fluorescence at 585 nm (excitation at 555 nm and cut-off at 
570 nm) was measured using the SpectraMax M2e Molecular Devices fluorescent plate 
reader.     
  
 3.2.4 Cell Cycle Analysis  Neil1+/+, Neil1+/-, and  Neil1-/- cells in the log 
phase of growth were exposed to chromate (0, 10, 20, 30, 50 µM concentrations) for 24 
hours in 75 cm2 flasks.  Flasks were rinsed with 1X PBS and harvested using Trypsin-
EDTA.  From this point forward, the cells were kept at 4oC unless otherwise noted.  Cells 
were transferred from flasks to 15 mL conical tubes and pelleted at 500 x g for 5 min.  
The supernatant was discarded and the pellet was washed with 1 mL of 1X PBS.  Cells 
were pelleted at 500 x g for 10 min.  The supernatant was discarded and the pellet was 
resuspended in ice cold 70% ethanol.  Each sample was mixed well before being stored at 
-20o C overnight.  Cells were pelleted at 1000 x g for 5 min. and the ethanol was 
discarded.  Samples were resuspended in 990 µL of hypotonic buffer (0.5% Triton X-100 
and 100 µg/mL RNAse A (Sigma) prepared in 1X PBS) and incubated on ice for 30 min.  
10 µL of a 500 µg/mL propidium iodide (Sigma) solution was then added and samples 
were allowed to incubate on ice for 30-60 min.  DNA content was analyzed by 
fluorescence at 617 nm (excitation at 535 nm and cut-off at 565 nm) in a FACScan laser 
flow cytometer (Becton Dickenson).   
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 3.2.5 BrdU TUNEL Assay  Neil1+/+ and Neil1-/- cells in the log phase of 
growth were exposed to chromate (0, 10, 20, 30, 50 µM concentrations) for 24 hours.  
Flasks were rinsed with 1X PBS and harvested using Trypsin-EDTA.  From this point 
forward, the cells were kept at 4o C unless otherwise noted.  Cells were transferred from 
flasks to 15 mL conical tubes and pelleted at 500 x g for 5 min.  The supernatant was 
discarded and the pellet was washed with 1 mL of 1X PBS.  Cells were pelleted at 500 x g 
for 10 min.  The supernatant was discarded and the pellet was resuspended in ice cold 
70% ethanol.  Each sample was mixed well before being stored at -20o C overnight.  Cells 
were pelleted at 1000 x g for 5 min. and the ethanol was discarded.  Pellets were 
resuspended in 0.5 mL of wash buffer provided in the APO-BrdU TUNEL Assay Kit 
(Invitrogen).  Samples were stained with an Alexa Fluor 488 anti-BrdU antibody and 
propidium iodide as directed in the APO-BrdU TUNEL Assay Kit.  Each sample had a 
final volume of ~600 µL.  Three 200 µL aliquots of each sample were added to a 96-well 
plate and fluorescence was measured on a SpectraMax M2e Molecular Devices 
fluorescent plate reader at 519 nm (excitation at 495 nm and cut-off at 510 nm) for the 
Alexa Fluor 488 stain and at 617 nm (excitation at 535 nm and cut-off at 565 nm) for the 
propidium iodide stain.      
 
 3.2.6 PARP-1 Assay Neil1+/+ and Neil1-/- cells were seeded at 1000 
cells/ml in 96-well plates and allowed to incubate for 48 hours.  Cells were exposed to 
chromate (0, 10, 20, 30, 50 µM concentrations) or a known apoptosis inducing agent, 
etoposide (50 µM concentration), for 24 hours.  Cells were washed with 1X PBS before 
cell extracts were obtained and labeled with anti-PAR antibody using the method outlined 
in the HT Chemiluminescent PARP/Apoptosis Assay (Trevigen).  PARP-1 activity in the 
form of PAR addition to histone proteins was then monitored as chemiluminescence at all 
wavelengths on a SpectraMax M2e Molecular Devices fluorescent plate reader.  
 
 3.2.7 Statistical Analysis Error bars in all of the graphs for chapters 3 and 4 
represent the standard deviation in the average values shown.  Figures 3.6 and 3.8 also 
have statistical data provided.  Statistical calculations were done using the Student’s two-
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tailed T-test assuming equal variance.  The number of observations gathered for the 
graphical representations is listed as “n” in the figure legends accompanying each graph.   
 
3.3 Results 
 
 3.3.1 Chromate Toxicity Neil1+/+, Neil1+/-, and Neil1-/- epithelial cells were 
exposed to Cr(VI) for 24 hours to observe their sensitivity to chromate. A toxicity curve 
was generated based on the percentage of cells that were still alive as compared to an 
untreated control sample following the 24 hour Cr(VI) exposure and a 22 hour incubation 
period in the CellTiter-Blue solution.  CellTiter-Blue is a solution of resazurin dye which 
is taken up by and reduced to resorufin by live cells.  Those cells that maintained an intact 
membrane were able to take up and reduce the resazurin dye to resorufin.  The 
fluorescence of the resorufin was monitored for 24 hours at 585 nm to determine the 
optimal length of time for exposure of the epithelial cells to this stain.  A maximal level of 
fluorescence was reached after 22 hours.   
 The epithelial cells were exposed to Cr(VI) concentrations ranging from 0 to 50 
µM.  The Neil1+/+ and Neil1+/- cell lines demonstrated similar responses to chromate 
exposure with an LD50 occurring at a Cr(VI) concentration of approximately 40 µM 
(Figure 3.4).  In contrast, the Neil1-/- cell line showed significantly greater tolerance to 
chromate than the Neil1+/+ and Neil1+/- cell lines at all Cr(VI) exposure levels except 1 
and 5 µM (Figure 3.4).  In a second trial, cells were dosed with chromate at 
concentrations between 50 and 100 µM to determine the LD50 for the Neil1-/- cell line and 
to determine at what point the two cell lines would again have equivalent survival 
percentages.  The LD50 for the Neil1-/- cell line was not reached until they had been 
exposed to a chromate concentration of nearly 70 µM.  Once the Neil1+/+ cells reached the 
50 µM exposure level, the amount of error in the data increased dramatically 
corresponding to a less than 50% cell survival rate.  This same trend was observed for the 
Neil1-/- cells except that the 50% cell survival rate was not reached until the 70 µM 
exposure level.  From that point forward, there is no longer any statistical difference in 
the cell survival percentages between the two cell lines.  The data from this additional 
toxicity trial is presented in figure 3.5.   
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Figure 3.4 – Toxicity curve for chromate exposure of the NEIL1 cell lines.  The Neil1-/- 
cell line shows reduced sensitivity to Cr(VI) as compared to the Neil1+/+ cell line.  The 
Neil1+/+ and Neil1+/- cell lines demonstrated similar responses to chromate exposure with 
the LD50 occurring at a Cr(VI) concentration of approximately 40 µM.  For each data 
point reported, n = 8 observations. 
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Figure 3.5 – Extended toxicity curve for chromate exposure of the NEIL1 cell lines.  The 
LD50 for the Neil1-/- cell line does not occur until a chromate concentration of nearly 70 
µM is reached.  The Neil1-/- cell line maintains a decreased sensitivity to chromate as 
compared to the Neil1+/+ cell line until an 80 µM dosage is reached.  From that point 
forward, there is no statistical difference in the sensitivity between the two cell lines.  For 
each data point reported, n = 8 observations. 
 
 
 
 3.3.2 Chromium Uptake Analysis NEIL1 deficient and proficient 
epithelial cells were dosed with chromate and then analyzed for uptake.  Harvested whole 
cells were digested and diluted so they could be analyzed by ICP-AES.  It was important 
to monitor chromium uptake in each of the NEIL1 cell lines to ensure that one cell line 
was not being exposed to higher intracellular chromium concentrations than the other.  
Chromate is taken up by cells through non-selective anion channels that normally regulate 
uptake of phosphate and sulphate.17  Cells that are actively growing will require a large 
amount of phosphate and sulphate for construction of proteins and nucleotides.  
Therefore, when chromate is present in the extracellular matrix, rapidly replicating cells 
will also inadvertently take in large amounts of chromate along with the influx of 
phosphate and sulphate.  Our ICP-AES data revealed that chromate uptake was equivalent 
between the NEIL1 cell lines at 5 and 50 µM extracellular exposure levels.  However, at 
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the intermediate exposure levels (10, 20, and 30 µM) there was a significant difference in 
chromate uptake but it was not always the Neil1+/+ cell line taking up larger amounts of 
chromate as we would have expected.  The Neil1+/+ cell line took up larger amounts of 
chromate than the Neil1-/- cell line at the 10 and 20 µM exposure levels but the Neil1-/- cell 
line took up more chromate at the 30 µM level as shown in figure 3.6. 
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Figure 3.6 – Chromium uptake was monitored on a pg of chromium/cell basis.  A 
statistically significant difference was observed for chromium uptake at 10, 20, and 30 
µM chromate exposure levels (* = 95% CL, # = 99% CL).  Neil1+/+ cells took up a 
greater amount of chromium at the 10 and 20 µM exposure levels and Neil1-/- cells took 
up a greater amount of chromium at the 30 µM level.  All cell lines took up equivalent 
amounts of chromium at the 5 and 50 µM exposure levels.  For each data point reported, n 
= 3 observations.      
 
 
 3.3.3 Cell Cycle Progression Following Chromate Exposure   
 Induction of DNA damage can lead to cell cycle arrest allowing cells to repair the 
damage before progressing further along in the cell cycle.  Chromate exposure induces 
DNA lesion formation and therefore exposure to chromate should cause cells to pause in 
the G0 or G2 arrest phases while the damage is assessed and/or repaired.  Similar to the 
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differences observed in sensitivity to chromate, Neil1+/+ and Neil1-/- cells also showed a 
difference in their progression through the cell cycle following chromate exposure.  At 
chromate exposure concentrations between 10 and 30 µM, the Neil1-/- cell line displayed 
elevated percentages of cells progressing into the S and G2/M phases of the cell cycle as 
compared to an untreated sample.  The Neil1+/+ cell line however, maintained similar 
percentages of its cells in the various phases of the cell cycle whether they had been 
exposed to chromate or not.  The heterozygous NEIL1 cell line data fell between that of 
the Neil1+/+ and Neil1-/- cell lines at each stage of the cell cycle analysis.  Figure 3.7a 
shows the data from the G0/G1 phase analysis, figure 3.7b shows the S phase data, and 
figure 3.7c shows the G2/M phase data.  Percentages of cells in each of the cell cycle 
phases were quantified based on propidium iodide (PI) fluorescence.  PI is a DNA 
binding fluorescent stain.  Cells were injected onto a FACScan laser flow cytometer and 
as they passed by the detector relative fluorescence was detected.  Cells with a single 
copy of DNA (G0/G1 phase) gave half the fluorescence counts of cells with two copies 
(G2/M phase).  Cells that were actively synthesizing DNA (S phase) gave fluorescence 
counts somewhere in between those of the G0/G1 and G2/M phase cells.     
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Figure 3.7a – All three NEIL1 cell lines have a similar percentage of cells in the G0/G1 
phase of the cell cycle under chromate free growth conditions and following exposure to a 
50 µM chromate concentration (80-90%).  The Neil1+/+ cell line maintains that same level 
of ~90% of cells in the G0/G1 phase at all chromate exposure levels.  The Neil1-/- cell line 
maintains only ~60% of its cells in the G0/G1 phase following exposure to 10, 20, and 30 
µM chromate concentrations. 
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Figure 3.7b – All three NEIL1 cell lines have a similar percentage of cells in the S phase 
of the cell cycle under chromate free growth conditions and following exposure to a 50 
µM chromate concentration (5-14%).  The Neil1+/+ cell line maintains that same level of 
only 5% of cells in the S phase at all of the chromate exposure levels but the Neil1-/- cell 
line maintains between 27-37% of its cells in the S phase following exposure to 10, 20, 
and 30 µM chromate concentrations. 
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Figure 3.7c – All three NEIL1 cell lines have a similar percentage of cells in the G2/M 
phase of the cell cycle under chromate free growth conditions and following exposure to a 
50 µM chromate concentration (6-8%).  The Neil1+/+ cell line shows a reduced percentage 
of cells in the G2/M phase (2%) following exposure to a 20 µM chromate concentration.  
However, the Neil1-/- cell line spikes to having as much as 12-16% of its cells in the S 
phase following exposure to 20 and 30 µM chromate concentrations. 
 
 
 3.3.4 Quantification of Free 3’-OH Ends  The presence of high numbers 
of free 3'-hydroxyl ends in DNA can indicate that a cell is undergoing a large amount of 
excision repair18 or that it has entered an apoptotic pathway which has lead to degradation 
of genomic DNA.19  Terminal deoxynucleotidyl transferase (TdT) is an enzyme that will 
add any deoxyribonucleotide to free 3'-hydroxyl ends.20  Using 5-bromo-2'-deoxyuridine 
5'-phosphate (BrdUTP) – a deoxythymidine analog – and TdT, free 3'-hydroxyl groups in 
genomic DNA can be efficiently labeled.  These groups can then be detected by further 
labeling the free 3'-hydroxl groups with an anti-BrdU antibody coated with an Alexa 
Fluor 488 fluorescent tag.  Epithelial cells from the NEIL1 proficient and deficient cell 
lines were analyzed for the presence of free 3'-hydroxyl ends using the above described 
transferase dUTP nick end labeling (TUNEL) technique.  Cells were also labeled with 
propidium idodide (PI, an intercalating fluorescent DNA stain) as a way to quantify total 
DNA allowing us to compare the amount of free 3'-hydroxyl ends relative to total DNA 
per sample.  All of the values were reported as a change in fluorescence from that of 
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untreated cell samples.  A control cell sample provided in the APO-BrdU TUNEL assay 
kit was also analyzed in a similar fashion.  The control cells were an HL60 cell line 
treated with camptothecin to induce apoptotic degradation of genomic DNA.  At all 
chromate concentrations investigated, the Neil1+/+ cell line showed an increase in the 
number of free 3'-hydroxyl ends over untreated Neil1+/+ cell samples.  There was no 
statistical difference observed in the number of free 3’-hydroxyl ends generated in the 
Neil1-/- cell samples for any of the chromate treatment concentrations versus those that 
were untreated.  The relative number of free 3'-hydroxyl ends in the Neil1+/+ cells 
exposed to 30 and 50 µM chromate concentrations was statistically equivalent to the 
relative number observed in the control, HL60 cells.     
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Figure 3.8 – Graphical representation of the number of free 3'-hydroxyl ends in genomic 
DNA of NEIL1 cell lines following exposure to chromate.  Values are reported as anti-
Brd-UTP fluorescence counts (Alexa Fluor 488) per PI fluorescence count.  All values 
represent difference in relative fluorescence from untreated NEIL1 proficient or deficient 
cell samples.  The * symbol indicates a statistical difference at the 99.9% confidence 
level.  A positive apoptosis control sample of HL60 cells treated with camptothecin is 
also shown.  For each data point reported, n = 6-9 observations. 
 
 
 3.3.5 PARP-1 Activity Poly (ADP-ribose) polymerase (PARP-1) is an 
enzyme that is involved in nuclear protein modification.  It catalyzes the transfer of poly 
(ADP-ribose) at DNA strand breaks.21  When apoptosis is initiated however, PARP-1 is 
cleaved from a 116 kDa to an 85 kDa protein by Yama/CPP32β [caspase 3].21  The 
cleaved PARP-1 enzyme then mediates the translocation of apoptosis inducing factor 
from the mitochondria to the nucleus.22  Uncleaved PARP-1 activity can be monitored by 
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measuring poly (ADP-ribose) deposition onto an immobilized protein, in this case histone 
proteins.  Based on the data from our BrdUTP TUNEL assay we knew that the NEIL1 
proficient cell line was accumulating a significantly higher level of free 3'-hydroxyl ends 
than the NEIL1 deficient cell line.  By monitoring PARP-1 activity in the two cell lines 
we were able to determine if that elevated level of free 3'-hydroxyl ends could be 
attributed DNA repair, as indicated by high levels of PARP-1 activity, or to apoptosis as 
indicated by depressed levels of PARP-1 activity.  Values were reported as mU of poly 
(ADP-ribose) per µg of total protein.  Total protein values for each cell sample were 
determined by BCA protein analysis using a Bicinchoninic Acid protein assay kit 
(Pierce).  PARP-1 activity values represent a difference in activity from that of untreated 
cell samples.  The NEIL1 proficient cells demonstrated an elevated PARP-1 activity level 
following exposure to a 10 µM chromate concentration but very low levels of activity 
following exposure to 20, 30 and 50 µM chromate concentrations.  The NEIL1 deficient 
cells had an opposite trend.  PARP-1 activity was reduced initially (10 µM chromate 
exposure level) and then increased dramatically (20, 30, and 50 µM chromate exposure 
levels).  A positive apoptotic control was also used as a comparison for PARP-1 activity.  
Both Neil1+/+ and Neil1-/- cells were exposed to a 50 µM concentration of etoposide a 
well-documented apoptosis inducing agent.23  Both cell lines showed similar trends in 
PARP-1 activity following treatment with etoposide as when they were treated with 20, 
30, and 50 µM concentrations of chromate in that PARP-1 activity was greatly reduced in 
the NEIL1 proficient cells relative to PARP-1 activity in the NEIL1 deficient cells.   
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Figure 3.9 – PARP-1 activity measured as poly (ADP-ribose) deposition on immobilized 
histones.  Neil1+/+ cells had elevated levels of PARP-1 activity at the 10 µM chromate 
exposure level relative to the Neil1-/- cells but this activity was truncated at all other 
exposure levels and in the etoposide control sample.  Neil1-/- cells showed an initial 
decrease in PARP-1 activity but elevated levels of activity relative to the Neil1+/+ cells at 
all other exposure levels and in the etoposide (C) treated samples.  For each data point 
reported, n = 3 observations.   
 
 
3.4 Discussion 
 
 3.4.1 Replication Coupled Base Excision Repair     BER glycosylases were 
once thought to all function in a similar, cell cycle independent manner.  Further studies 
of these repair enzymes have shown that there are actually two distinct groups of BER 
glycosylases that carry out two slightly different forms of BER.  The classical form of 
BER is now referred to as single nucleotide base excision repair (SN-BER).24  The SN-
BER pathway utilizes apurinic/apyrimidinic endonuclease 1 (APE-1) to process a β-
elimination product or polynucleotide kinase (PNK) to process a βδ-elimination product 
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formed by a BER glycosylase.25  DNA polymerase β will then insert a new base using the 
complementary strand as a template and the gap in the phosphate backbone will be sealed 
by DNA ligase IIIα.26  This type of BER occurs in DNA that is not being actively 
replicated and as such, does not utilize replication associated DNA polymerases or 
ligases.  In fact, it has been reported that the BER glycosylases OGG1 and NTH1 are not 
even functional in single stranded DNA or replication bubble structures.27  Therefore, it 
was of no surprise that although OGG1 and NTH1 function to remove oxidized 
nucleobase lesions (Table 1.3), their expression has been shown to be cell cycle 
independent.  NEIL1 however, belongs to a second group of BER glycosylases that are 
cell cycle regulated and function as part of a modified BER pathway linked to DNA 
replication. 
 The second form of BER that has been identified is now defined as long patch 
base excision repair (LP-BER).28,29  This second BER pathway functions in a very similar 
manner to SN-BER except that it is active only during DNA synthesis.24  Since LP-BER 
is utilized during DNA synthesis, the accessory proteins involved in this repair pathway 
are proteins that are also involved in replication of undamaged DNA.  SN-BER requires 
the use of DNA polymerase β as it contains intrinsic β-lyase activity that facilitates the 
removal of the 5’-terminal region formed by β- or βδ-elimination prior to insertion of a 
new base.26  This step is undertaken by flap endonuclease 1 (FEN1) in LP-BER30 so that 
DNA polymerases δ and ε, which are already being employed for DNA replication, can 
fill in the AP site with a new base and then continue their progress along the DNA 
template being actively replicated.28,29  The gap in the phosphate backbone will be sealed 
by DNA ligase I which is also part of the normal DNA replication machinery.31 
 A major difference between the two forms of BER is that SN-BER is carried out 
by individual proteins in relatively discrete steps whereas, LP-BER is carried out within a 
large protein complex in which repair and replication proteins may remain associated 
throughout the entire replication process.  A DNA sliding clamp protein directs the 
assembly and functionality of the replication complex.  Proliferating cell nuclear antigen 
(PCNA) is one DNA sliding clamp of particular interest to our research as it has been 
demonstrated that NEIL1 strongly associates with PCNA24 as do several other BER 
glycosylases (MYH and UDG) that like NEIL1 are also cell cycle regulated.32  Once 
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loaded onto the DNA by replication factor C (RFC), PCNA then recruits replication 
proteins such as DNA helicases, topoisomerases, polymerases, and glycosylases to 
assemble into a large replication complex, thus initiating DNA synthesis.33  
 DNA synthesis will come to a halt when a lesion is encountered in the template 
strand.  Chromate may cause a variety of bulky lesions such as oxidatively induced 
protein-DNA crosslinks, and DNA-DNA crosslinks.  These lesions will typically recruit 
nucleotide excision repair (NER) before synthesis has been initiated as they will 
extensively perturb the natural structure of B-form DNA acting as a beacon for repair 
systems.  If these bulky lesions are still present when DNA replication is initiated, the 
replication complex will be unable to read through those points of damage.27  Those bulky 
lesions would then have to be repaired before the replication complex could be 
reassembled and proceed with DNA synthesis.  Small oxidative base lesions however, can 
easily go undetected in the genome prior to DNA replication as they do not greatly disturb 
the native DNA structure.27  Therefore, it is very likely that a replication complex will 
encounter un-repaired oxidative base lesions such as Sp and Gh in genomic DNA from 
cells exposed to chromate.  These lesions will cause the replication complex to stall long 
enough to either repair the lesion, or since the lesions are small, to read through the point 
of damage.   
NEIL1, but not NEIL2, production is up-regulated during the S phase of the cell 
cycle.34,35  NEIL1, but not NEIL2, has also been shown to be stimulated by PCNA24 
indicating that NEIL1 should be the glycosylase of choice to repair chromate induced 
oxidative lesions such as Sp and Gh that are encountered during DNA replication.  
Whether or not NEIL1 is part of the PCNA mediated replication complex from the initial 
point of assembly until the completion of DNA synthesis, or if it is only recruited when 
an oxidative lesion is encountered is still unknown.  It has been demonstrated though that 
NEIL1 activity is stimulated by PCNA,24 the DNA replication helicase Werner syndrome 
protein (WRN) that is associated with the PCNA complex,36,37 and by the Rad9-Rad1-
Hus1 (9-1-1 complex) another DNA sliding clamp protein that carries out functions 
similar to those of PCNA.38  When an Sp or Gh lesion is encountered during replication, 
NEIL1 would be required to excise the lesion while the replication complex was 
temporarily stalled.  If NEIL1 is not present to repair the lesion, PCNA has the ability to 
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recruit DNA polymerase η (a damage tolerant polymerase)39 to simply insert any base 
across from the Sp or Gh lesion so that DNA synthesis can continue through the 
essentially non-disruptive damage point.  It is beneficial for the PCNA complex to 
facilitate insertion of a single base mutation rather than to break apart because the 
replication fork can then collapse completely forming a double strand break.  A double 
strand break requires recombination for repair40 which can lead to the loss of critical 
genetic information when the template for recombination includes incomplete nascent 
DNA strands.   
When an Sp or Gh lesion is encountered and NEIL1 is present, the replication 
complex would temporarily stall and the replication fork would partially collapse forming 
a “chicken foot” structure40 in which the DNA template strands just down stream of the 
“chicken foot” would re-anneal.41  NEIL1 would then bind to and excise the Sp or Gh 
lesion.  PNK could then process the AP site, FEN1 could process the 5’-terminal region, 
polymerase δ/ε could insert a new base, and DNA ligase I could seal the nick in the 
phosphate backbone.  A DNA helicase such as WRN would once again denature the DNA 
down stream of the “chicken foot” and PCNA would reinitiate DNA synthesis.41   
 
3.4.2 Implications of NEIL1 Deficient Epithelial Cell Data Our initial 
hypothesis concerning the NEIL1 deficient murine epithelial cells was that they would 
show increased sensitivity to chromate relative to their wild type counterpart as was 
observed in Nei deficient E. coli.15  However, this cell line actually showed reduced 
sensitivity to chromate with respect to the NEIL1 proficient cell line.  This led us to 
believe that NEIL1 must play a more complex role in maintenance of cellular homeostasis 
than a classical mammalian BER glycosylase and or a BER glycosylase in a prokaryotic 
system.  The recent work outlined above shows that NEIL1 does in fact play a different 
role in BER than OGG1 or NEIL2 in that NEIL1 functions to repair oxidized nucleobase 
lesions in actively replicating DNA whereas OGG1 and NEIL2 carry out this function in 
non-replicating DNA.  Since NEIL1 is tied to replication, it is also inherently linked to the 
cell cycle.  This proposal is supported by the findings that expression of NEIL1 is 
stimulated during the S phase of the cell cycle.34,35   
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Our data revealed that NEIL1 deficient cells not only display reduced sensitivity 
to chromate but that they also show aberrant cell cycle affects following chromate 
exposure.  The DNA damage induced by chromate should cause a cell to pause and assess 
damage before moving along in the cell cycle, or in other words it should enter a period of 
cell cycle arrest.  While we did not observe a large increase in the percentage of NEIL1 
proficient cells stalling in the G0/G1 phases, we did see a decrease in the percentage of 
NEIL1 deficient cells in the G0/G1 phases following exposure to chromate.  That 
decrease in cells in the G0/G1 phases correlated with an increase in the percentage of 
NEIL1 deficient cells found in the S and G2/M phases following exposure to chromate.  
This data suggests not only that chromate exposure does not hinder NEIL1 deficient cells 
from progressing through the S phase, it appears to stimulate cell cycle progression.  This 
is occurring despite the fact that they would be accumulating significantly more oxidative 
DNA lesions than NEIL1 proficient cells.  Thus, NEIL1 must play an essential role in 
oxidative DNA lesion detection, signaling the cell to postpone cell cycle progression 
while the damage is assessed and repaired.  This proposal is supported by the fact that 
DNA replication complexes have the potential to read through small nucleobase lesions24 
if they are not repaired immediately following the encounter of a nucleobase lesion by the 
repair complex.  By employing damage tolerant polymerase η that will simply insert any 
base across from the small nucleobase lesion, the replication complex can continue its 
processivity along the DNA template without risking replication fork collapse and double 
strand break formation.39   
NEIL1 deficient cells not only display altered cell cycle characteristics following 
exposure to chromate, they also appear to be apoptosis resistant.  When a large amount of 
DNA damage accumulates in a cell, p53 should signal the cell to switch from a survival 
pathway that would involve DNA repair, to an apoptotic pathway that will eventually end 
with the orderly degradation of genomic DNA.8  The NEIL1 deficient cells, unlike the 
NEIL1 proficient cells do not appear to receive that apoptotic signal following exposure 
to levels of chromate that are ultimately toxic to the NEIL1 proficient cells.  A large 
number of oxidative nucleobase lesions induced by reduced chromate in the cell would go 
undetected prior to DNA replication because lesions like Sp and Gh are relatively small, 
non-disruptive structures.  During synthesis, DNA is progressively scanned by the 
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replication complex, so any lesions not repaired prior to replication will be encountered 
and will then be repaired or expressed as a mutation in the newly synthesized DNA.  It 
would be the job of NEIL1 to repair any Sp or Gh lesions encountered during replication 
by utilizing the LP-BER pathway.  However, if NEIL1 is absent from the replication 
complex, it is likely that a single base mutation would be inserted opposite the lesion by 
polymerase η allowing the replication process to continue.   
Reading through nucleobase lesions would allow a large number of mutations to 
build up in the newly synthesized DNA.  The actual repair of such lesions before they can 
be expressed as mutations, must then act as a signaling method.  If too much repair is 
going on, a cell may receive signals that it is too badly damaged to salvage its DNA 
successfully so p53 would direct the cell into an apoptotic pathway.  Without NEIL1 
present, cells damaged by chromate exposure would not receive such a signal and would 
therefore continue to replicate as if nothing were amiss.  Essentially, they would become 
apoptosis resistant.  All the while, mutations would begin to accumulate in the newly 
synthesized DNA.  Thus apoptosis resistance in the NEIL1 deficient cells would allow for 
accumulation of mutations that could eventually render the cells independent of cell cycle 
checkpoints or in other words a cancerous cell may be created.  For this reason, apoptosis 
resistance is often referred to as a hallmark of cancer.  
 
3.5 Conclusions 
  
 NEIL1 deficient murine epithelial cells display an increased tolerance for 
chromate.  They also did not enter cell cycle arrest following exposure to chromate and 
displayed characteristics of apoptosis resistance.  Apoptosis resistance following 
chromate exposure would allow the NEIL1 deficient cells to accumulate mutations that 
can act as initiators for cancer.  If these mutations accumulate in genes required for cell 
cycle control, gene transcripts would be altered and the cancer promotion stage would be 
reached.  Studies have shown that deletions in the 15q chromosome arm – the location of 
the NEIL1 gene - are observed in more than 70% of human small cell lung carcinomas.16  
Lung cancers have been the major reported form of cancer caused by chromate 
exposure.42-45  Therefore, people that carry mutations in their NEIL1 gene would stand a 
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higher risk of developing cancer from chromate exposure than those with two fully 
functional NEIL1 gene alleles.  These conclusions are based on the assumption that the 
NEIL1 deficient cells accumulate oxidized base lesions following chromate exposure 
since they do not enter the apoptotic pathway even after they have been exposed to levels 
of chromate that lead to more than 50% toxicity in NEIL1 proficient cells.  Accumulation 
of mutations in the NEIL1 deficient cell lines will be discussed in the Chapter 4.     
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CHAPTER 4 
Lesion and Mutation Accumulation in NEIL1 Cell Lines 
 
4.1 Introduction 
  
 The formation of oxidative DNA lesions in a cellular system may act as an 
initiator for mutation formation if the lesions are not repaired.  Single oxidative 
nucleobase lesions can be potent sources for mutations as they do not typically cause a 
large disruption in the overall structure of B-form DNA1 and can be overlooked prior to 
transcription or replication of DNA.  For example, an 8-oxoG lesion maintains a planar 
ring structure similar to that of the four natural DNA bases G,C, T, and A.  The N7 group 
is simply shifted from being a hydrogen bond acceptor to a hydrogen bond donor.  
Because the N7 group is not directly involved with the Watson-Crick hydrogen bonding 
between a normal guanine residue and a cytosine residue, an 8-oxoG lesion can still 
stably pair with a cytosine residue (Figure 4.1a).  During a round of replication, the 8-
oxoG lesion may be flipped into the syn conformation by DNA polymerases and will then 
be paired with an adenine residue (Figure 4.1b) leading to the formation of a G:C → T:A 
transversion mutation.2   
 While 8-oxoG has been shown to induce G:C → T:A transversion mutations,2,3 
the hydantoin lesions, Sp and Gh/Ia, have been shown to cause those same transversion 
mutations at frequencies at least one order of magnitude higher.4  In addition to G:C → 
T:A transversion mutations, Sp and Gh/Ia have also been shown to induce G:C → C:G 
transversion mutations4-6 and are >98% mutagenic whereas 8-oxoG is approximately 5% 
mutagenic.4,6,7  The Sp and Gh/Ia lesions have a significantly altered structure relative to 
that of the parent guanine residue or an 8-oxoG lesion (Figure 4.2) making it more 
difficult for these lesions to form appropriate hydrogen bonding schemes that do not 
perturb the overall DNA structure.  Since these lesions would create a more substantial 
alteration in the DNA structure, they should theoretically be easier for the SN-BER 
pathway to detect and repair prior to DNA replication.  Sp lesions however, are identified 
and excised by the NEIL1 glycosylase.8  NEIL1 expression is up-regulated during the S 
phase9,10 and has been shown to associate with replication complex proteins indicating 
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that NEIL1 is involved in LP-BER rather than SN-BER.11-14  Therefore, Sp lesions, 
despite their tendency to create a more dramatic kink in the DNA phosphate backbone 
than an 8-oxoG lesion, would typically not be repaired until a cell entered S phase 
increasing the odds that a point mutation could be generated opposite an Sp lesion. 
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Figure 4.1a – Watson-Crick base pairing between guanine and cytosine and between 8-
oxoG and cytosine.  The N7 group of the 8-oxoG lesion is altered from a hydrogen bond 
acceptor (A) to a hydrogen bond donor (D) location.  This alteration does not significantly 
alter the ability of 8-oxoG to pair with a cytosine residue. 
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Figure 4.1b – An 8-oxoG lesion can be paired with a cytosine or an adenine residue 
during DNA replication.  If the polymerases flip the 8-oxoG lesion into a syn 
conformation, it will be paired with an adenine initiating a G:C → T:A transversion 
mutation. 
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Figure 4.2 – An 8-oxoG lesion maintains a planar, two-ring structure similar to that of the 
four natural DNA bases.  The Sp lesion maintains a two-ring structure but the ring 
systems sit at a 90 degree angle to one another and thus disrupt the planar, stacked 
conformation of duplex DNA.  During the formation of an Gh/Ia lesion, one ring opens. 
   
 
 
 Since repair of Sp is tied to the process of replication, DNA polymerase δ/ε will 
fill in the AP site once the lesion has been excised by NEIL1 and the termini have been 
processed by PNK15 or FEN1.16  Lesions such as 8-oxoG, will be replaced by DNA 
polymerase β following excision via the SN-BER pathway.17  Studies have been 
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conducted with these different polymerases to determine their accuracy in inserting a 
specific base when the template nucleotide is an unrepaired lesion.  It was reported that 
pol β (the non-replication associated DNA repair polymerase) favored insertion of the 
correct, dCMP residue across from an 8-oxoG lesion whereas pol δ (the replication 
associated DNA polymerase) favored insertion of dAMP.18  This study indicated that 
DNA replication polymerases would be more prone to insertion of point mutations than 
DNA repair polymerases suggesting that unrepaired lesions such as Sp, would be highly 
mutagenic when encountered during replication. 
 NEIL1 deficient murine epithelial cells show reduced sensitivity to chromate and 
cell cycle aberrations including apoptosis resistance.  Without the NEIL1 glycosylase 
present to excise Sp lesions formed by oxidation of guanine residues by high valent 
chromium species, the NEIL1 deficient cell line should accumulate point mutations.  The 
level of DNA repair in these cells should be attenuated possibly masking the extent of the 
damage which was shown to be extensive enough to initiate an apoptotic cascade in 
NEIL1 proficient cells.  Instead of entering an apoptotic pathway, the NEIL1 deficient 
cells continued to grow and divide even following exposure to chromate concentrations 
that were far more than 50% lethal for the NEIL1 proficient murine epithelial cell line.  
We thus anticipated that we would see an accumulation of point mutations in correlation 
with an accumulation of Sp lesions in the NEIL1 deficient cells.  To begin, we analyzed 
the cells for 8-oxoG levels following chromate exposure.  We did not observe a 
significant difference in the maximal level of accumulated 8-oxoG lesions as expected 
since the mOGG1 glycosylase was functional in both cell lines.  We also analyzed an 
MCF-7 (human breast cancer cell line) for 8-oxoG accumulation following chromate 
exposure.  This was done as a way to compare the trends observed in our 8-oxoG data 
with another mammalian cell line with functional Ogg1 and Neil1 genes.  Accumulation 
of point mutations was analyzed using an Hprt forward mutation assay.    
 
4.2 Materials and Methods 
 
 4.2.1 MCF-7 Cell Line Growth Conditions MCF-7 cells were purchased 
from ATCC.  Cells were grown in DMEM containing 4.5 g/L D-glucose, L-glutamine, 
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and 110 mg/L sodium pyruvate (Gibco) which was supplemented with 10% fetal calf 
serum (HyClone), 1% 100X antibiotic-antimycotic (Gibco), 0.1 mM non-essential amino 
acids (Gibco), and 10 µg/mL insulin (Sigma, pH 8.2).  Cells were maintained at 37o C 
under an atmosphere of 5% CO2.   
 
 4.2.2 Cell Treatment Neil1+/+ and Neil1-/- murine kidney epithelial cells as 
well as MCF-7 cells were exposed to Cr(VI) for 4 hours.  The concentrations used for the 
murine epithelial cell lines were 0, 10, 15, 25, 50 µM in correlation with the toxicity curve 
obtained for those cell lines.  MCF-7 cells were exposed to Cr(VI) at levels of 0, 10, 25 
and 50 µM and/or to 100 nM 17β-estradiol (Sigma, E2) levels either alone or in 
conjunction with Cr(VI) exposure.  E2 exposure time was 48 hours with Cr(VI) being 
applied for the final 4 hours of the treatment period.     
 
 4.2.3 Genomic DNA Extraction Neil1+/+, Neil1-/- epithelial cells and MCF7 
cells were washed with 1X PBS and harvested using Trypsin-EDTA as outlined 
previously.  Cell samples were pelleted at 300 x g and the supernatant was discarded.  
Each 15 mL conical tube was placed on ice followed by the addition of 1 mL of 4o C 
DNA extraction buffer (0.1 M Tris-HCl, 0.1 M NH4Cl, pH 8.0).  Cell pellets were mixed 
thoroughly but gently and were then sonicated for 5 min. in a Branson 3200 sonicating 
water bath.  Cell samples were pelleted at 2400 x g (4o C) for 5 min. and the supernatant 
was discarded.  Pellets were resuspended in 300 µL of DNA extraction buffer containing 
33 U of RNAse T1 (Sigma) and 200 µg of RNAse A (Sigma) and incubated at 37o C for 1 
hour.  300 µL of DNA extraction buffer containing 300 µg of Proteinase K (Invitrogen) 
and 1% SDS was then added.  The samples were mixed thoroughly but gently and 
allowed to incubate for an additional 1 hour at 37o C.  750 µL of concentrated phenol (pH 
7.9, Sigma) was then added and each sample was vigorously mixed before the organic 
and aqueous phases were separated by centrifugation at 2400 x g for 5 min.  The 
supernatant was removed and placed into a fresh 1.5 mL tube, mixed vigorously with 250 
µL of a 25:24:1 phenol : chloroform : isoamyl alcohol solution (pH 7.9, EMD), and 
separated by centrifugation at 12000 x g for 5 min.  Again the supernatant was removed 
and placed into a fresh 1.5 mL tube, mixed vigorously with 250 µL of a 24:1 chloroform : 
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isoamyl alcohol solution (Sigma), and separated by centrifugation at 12000 x g for 5 min.  
The supernatant was mixed with 30 µL of 10 M ammonium acetate (pH 5.0) and 1 mL of 
-20o C 100% ethanol in a fresh 1.5 mL tube.  Samples were mixed and DNA was allowed 
to precipitate at -20o C overnight before being pelleted at 12000 x g (4o C) for 15 min.  
The 100% ethanol was discarded and pellets were washed with 1 mL of -20o C 70% 
ethanol.  DNA was pelleted at 12000 x g (4o C) for 10 min.  The 70% ethanol was 
discarded, residual liquid was dried and the pellet was resuspended in 100 µL of 
deionized water.  Absorbance at 260 nm (OD260) was obtained for each DNA sample in 
order to determine the DNA content of each sample.  
 
 4.2.4 DNA Hydrolysis DNA samples were denatured by heating to 95o C 
for 5 min. followed by flash cooling on ice for 3 min.  Within one minute of being placed 
on ice, 0.1 U of phosphodiesterase II (Worthington Biochemicals) prepared in deionized 
water was added to each DNA sample.  Samples were allowed to incubate at 37o C for 45 
min.  Addition of phosphodiesterase II and incubation at 37o C for 45 min. was repeated.  
0.5 U of phosphodiesterase I (Worthington Biochemicals) buffered in 10 mM Tris-HCl, 
10 mM NH4Cl, 1.5 mM MgCl, pH 8.9 was added to each sample and they were allowed 
to incubate for 45 min. at 37o C.  Addition of phosphodiesterase I followed by incubation 
at 37o C for 45 min. was repeated.  5 U of calf intestinal phosphatase (Promega) buffered 
in 50 mM Tris-HCl, 1 mM MgCl2, 0.1 mM ZnCl2, 1 mM spermidine, pH 9.3 was added 
to each sample and they were allowed to incubate for 45 min. at 37o C.  Addition of calf 
intestinal phosphatase followed by incubation at 37o C for 45 min. was repeated.  Samples 
were cleaned up in YM-30 centrifugal filters (Microcon) by centrifugation at 2500 x g for 
25 min.  Samples were stored at -80o C until analysis.    
 
 4.2.5 8-oxoG Quantification 8-oxoG lesions were quantified and reported 
as values relative to the amount of guanine present in each hydrolyzed DNA sample.  
Hydrolyzed DNA samples were analyzed using an Agilent 1200 series HPLC coupled 
with diode array detection for guanine quantification.  Samples were separated using an 
Agilent C18 4.6 mm x 100 mm column, with an isocratic mobile phase of 100 mM 
ammonium acetate (pH 5.2) and 4% methanol at a flow rate of 1 mL/min.  A calibration 
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curve for guanine was generated from standards of dG ranging from 125 ng to 2500 ng.  
The dG content of the hydrolyzed DNA samples was calculated by comparing dG peak 
areas from 25 µL aliquots of hydrolyzed samples to the calibration curve.  Separated 
DNA was then further analyzed using an ESA CoulArray electrochemical detector.  
Hydrolyzed DNA was subjected to four different voltages (50, 100, 150, 300 V) as it 
passed across a model 6210 ESA electrical cell.  8-oxoG was oxidized in the 300 V 
channel.  A calibration curve for 8-oxoG was generated from standards of 8-oxoG ranging 
from 25 pg to 625 pg.  The 8-oxoG content of the hydrolyzed DNA samples was 
calculated by comparing 8-oxoG peak areas from 25 µL aliquots of hydrolyzed samples to 
the calibration curve.   
 
 4.2.6 Hprt Mutation Analysis  Resistance to 6-thioguanine (Sigma, 6-TG) 
was assessed in both the Neil1+/+ and Neil1-/- cell lines using a fluorescence 96-well plate 
assay.  Cells were seeded in 96-well plates at a density of 1 x 104 cells/mL and allowed to 
recover for 48 hours before being treated with 6-TG.  Media was removed from the 96-
well plates and 6-TG solutions were added with the final concentrations of 6-TG being 0, 
5, 10, 20, 30, 40, 50, 60, 70 and 80 µg/mL.  Plates were allowed to incubate for 24 hours.  
6-TG solutions were removed and each plate was then rinsed with 1X PBS.  CellTiter-
Blue (Promega) was mixed with complete media to form a 10% CellTiter-Blue solution.  
200 µl of this solution was added to each well in the 96-well plates.  Plates were allowed 
to incubate in the CellTiter-Blue solution for 22 hours at which time fluorescence at 585 
nm (excitation at 555 nm and cut-off at 570 nm) was measured using a SpectraMax M2e 
Molecular Devices fluorescent plate reader.    
1 x 106 of cells from each cell line were seeded in 75 cm2 flasks and allowed to 
recover for 24 hours.  Cells were dosed with chromate for 24 hours (0, 5, 10, 20, 30 and 
50 µM).  Flasks were then washed with 1X PBS, refreshed with complete chromate-free 
media and allowed to recover for 5 days.  1 x 106 cells from each cell line and treatment 
level were seeded in 25 cm2 flaks.  Complete media was supplemented with 20 µg/mL 6-
TG.  Media, supplemented with 6-TG, was refreshed every 3-4 days. Cells were allowed 
to incubate for 7 days or until colonies had formed.  Media was then aspirated and cells 
were incubated in a 2% methylene blue solution (100 mg methylene blue (Sigma) 
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prepared in 50 mL of 50% ethanol) for five minutes.  The methylene blue solution was 
rinsed with deionized water and colonies were counted.  Following recovery from 
chromate treatment, Neil1+/+ and Neil1-/- cells were also seeded in 60 mm dishes at a 
density of 400 cells/plate to monitor plating efficiencies.  These cells were also allowed to 
incubate for 7 days or until colonies had formed at which time they were stained with 2% 
methylene blue and counted.     
 
4.3 Results 
 
 4.3.1 8-oxoG Quantification Hydrolyzed DNA samples from both the 
Neil1+/+ and the Neil1-/- cell lines were analyzed by diode array for guanine content 
(Figures 4.3 and 4.4) and electrochemical detection for 8-oxoG content (Figure 4.5) 
following exposure to chromate for 4 hours.  Guanine and 8-oxoG content were 
quantified by measuring peak area and comparing those values to a standard curve.  New 
guanine and 8-oxoG standards were analyzed prior to each analysis of the hydrolyzed 
DNA if all samples could not be run in a single session.   
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Figure 4.3 – HPLC traces from a guanine standard (upper trace) and a digested DNA 
sample (lower trace).  Guanine eluted at approximately 8.5 min. in both samples.  All four 
DNA bases were visible in the digested DNA sample trace indicating that the DNA 
hydrolysis was effective.     
 
  
 
 
Figure 4.4 – Guanine was identified by its characteristic ultraviolet absorbance spectrum. 
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Figure 4.5 – 8-oxoG elutes at 10 min. in channel 4.  8-oxoG is oxidized only in channel 4 
of the electric cell at 300 V.  
 
 
 
 
Both cell lines showed an initial increase in the number of 8-oxoG lesions present relative 
to the total number of guanine residues in each sample as compared to levels of 8-oxoG 
observed in the control samples.  This increase was seen in the Neil1+/+ cell line only 
between the untreated samples and the samples dosed with 10 µM chromate.  The levels 
of 8-oxoG in NEIL1 proficient cells dropped back to a level equivalent with that seen in 
the untreated samples following exposure to 15, 25, and 50 µM chromate concentrations.  
The increase in the relative level of 8-oxoG lesions present in the Neil1-1- cell line 
increased in a dose dependent fashion over the untreated sample values following 
exposure to both 10 and 15 µM chromate concentrations.  After exposure to a 25 µM 
chromate solution, the 8-oxoG levels in the NEIL1 deficient cell line fell from the level 
seen in the samples dosed with 15 µM chromate.  8-oxoG levels in the NEIL1 deficient 
cell line also returned to a level equivalent to that observed in the untreated samples but 
only after being exposed to a 50 µM chromate solution.  There was no significant 
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difference observed in the maximum level of accumulated 8-oxoG lesions between the 
two epithelial cell lines.  This data is presented in figure 4.6.   
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Figure 4.6 – 8-oxoG lesions relative to the total number of guanine residues present in 
hydrolyzed DNA samples from NEIL1 epithelial cell lines exposed to chromate for 4 
hours.  Both cell lines show an initial, dose dependent increase in the level of 8-oxoG 
lesions present but that increase is followed by a decrease back to levels equivalent to 
those observed in the untreated samples.  For each data point reported, n = 3-5 
observations. 
 
 
 
 
 Hydrolyzed DNA from MCF-7 cells dosed with chromate and/or E2 were also 
analyzed by electrochemical detection.  E2 is a female hormone that has been shown to 
induce ROS production in cells and to cause breast cancer development.19,20  The MCF-7 
DNA samples demonstrated a similar trend in 8-oxoG levels relative to total guanine 
residues as was seen in the NEIL1 DNA samples.  Following exposure to chromate alone, 
8-oxoG levels in the MCF-7 cells increased initially (10 µM chromate dose) relative to 
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the level seen in untreated samples.  The 8-oxoG levels then decreased following 
exposure to 25 and 50 µM chromate concentrations.  Samples dosed with E2 alone 
developed higher 8-oxoG levels than untreated samples.  The levels following E2 
exposure were equivalent to those observed in samples dosed with 25 and 50 µM 
chromate alone.  Treating MCF-7 cells with both chromate and E2 caused a steep drop off 
in the level of 8-oxoG lesions present.  8-oxoG levels in samples dosed with 100 nM E2 
and 15 µM chromate fell below the level of 8-oxoG lesions observed in untreated 
samples.  This data is shown in figure 4.7. 
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Figure 4.7 – 8-oxoG lesions relative to the total number of guanine residues present in 
hydrolyzed DNA samples from MCF-7 cells exposed to chromate for 4 hours and/or E2 
for 48 hours.  8-oxoG levels increase relative to those seen in untreated samples following 
exposure to a 10 µM chromate solution and after exposure to E2 alone.  The levels of 8-
oxoG drop off dramatically following exposure to both chromate and E2 to levels lower 
than that observed in the untreated samples.  For each data point reported, n = 3-4 
observations.  
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 4.3.2 Hprt Mutation Assay Chromate treated cells from both the 
Neil1+/+ and Neil1-/- cell lines were allowed to recover for 5 days in chromate-free 
complete media before being seeded in 60 mm dishes at a density of 400 cells per dish to 
assess plating efficiency.  These cells were maintained in 6-TG-free media for 6 days at 
which time colonies had formed.  Colonies were then stained and counted.  The untreated 
cells from both the NEIL1 proficient and deficient cell lines formed equivalent numbers 
of colonies after 6 days (Figure 4.8a).  This was followed by a slight increase in cell 
colony formation in both cell lines for cells exposed to 5 µM chromate.  The Neil1+/+ 
dishes then showed a steady decrease in the number of colonies forming in conjunction 
with chromate treatment concentrations of 10, 20, 30, and 50 µM.  The Neil1-/- cell dishes 
showed a slight decrease in colony formation at the 10 µM treatment level but then a 
significant increase in colony formation at the 20 and 30 µM treatment levels.  Colony 
numbers fell back to the level observed in the untreated Neil1-/- dishes for cells treated 
with 50 µM chromate.  The same trends presented themselves when colony formation was 
represented as a percentage of colonies in the control dishes (Figure 4.8b).  Error in this 
data was quite high because of the small number of colonies that formed in the dishes.  
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Figure 4.8 – A similar number of colonies were counted in dishes containing untreated 
Neil1+/+ and Neil1-/- cells.  Cell growth was initially stimulated in both cell lines at the 5 
µM chromate treatment level but then steadily declined for the Neil1+/+ cell line.  Growth 
continued to be stimulated by chromate exposure in the Neil1-/- cell line through the 30 
µM chromate treatment level with colony formation dropping back to near control levels 
following exposure to 50 µM chromate.     
 
 
 
 
 Mutation accumulation in the Hprt gene was assessed by seeding 1 x 106 cells in 
25 cm2 culture flasks for both the Neil1+/+ and Neil1-/- cell lines following chromate 
treatment and a 5 day recovery period.  These cells were then maintained for 7 days in 
media supplemented with 20 µg/ml 6-TG.  In order for cells to grow and form colonies in 
the presence of 6-TG, they must have first developed mutations in the Hprt gene.  No 
quantitative data was able to be obtained for comparisons between the Neil1+/+ and   
Neil1-/- cell lines in this assay but some qualitative observations could be made.  No 
colonies formed in any of the Neil1+/+ culture flasks (Figure 4.9a) indicating that 6-TG 
was toxic to these cells even following exposure to chromate.  Colonies did form in flasks 
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seeded with Neil1-/- cells exposed to 0, 5, 10 and 20 µM chromate (Figure 4.9a-B).  
Colonies did not form in flasks seeded with Neil1-/- cells dosed with 30 and 50 µM 
chromate, instead the cells grew to confluence (Figure 4.9b).  Since colonies did form in 
the Neil1-/- culture flasks dosed with 0, 5, 10, and 20 µM chromate, a quantitative trend in 
colony number could be presented graphically (Figure 4.10).  Colony formation initially 
increased for flasks at the 5 µM chromate exposure level but then fell back to control 
values by the 20 µM chromate exposure level.  
 
 
 
 
 
Figure 4.9a – Differences in colony formation between (A) Neil1+/+ and (B) Neil1-/- cells.  
Both flasks were seeded with 1 x 106 cells that had not been exposed to chromate and 
were then grown in media supplemented with 20 µg/ml 6-TG for 7 days.  Neil1+/+ culture 
flasks looked identical for all chromate exposure levels.   
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Figure 4.9b – Differences in colony formation between (A) Neil1-/- cells dosed with 30 
µM chromate and (B) Neil1-/- untreated cells.  Both flasks were seeded with 1 x 106 cells 
and grown in media supplemented with 20 µg/ml 6-TG for 7 days.  Neil1-/- culture flasks 
for the 0, 5, 10, and 20 µM chromate exposure levels looked similar to (B) but with 
varying numbers of colonies present.  Neil1-/- culture flasks for the 30 and 50 µM 
chromate exposure levels looked identical to (A). 
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Figure 4.10 – Colony formation trends for the Neil1-/- cell line maintained in media 
supplemented with 20 µg/ml 6-TG for 7 days following treatment with chromate.  Colony 
numbers increase over control levels at the 5 µM chromate exposure level and then began 
to fall back to control values by the 20 µM chromate exposure level.   
 
  
4.4 Discussion  
 
 4.4.1 Formation and Detection of Further Oxidized Lesions In studies 
conducted in E. coli, Sp lesions, but not 8-oxoG lesion, were observed to accumulate in 
an Nei deficient E. coli strain.21  Based on that information, we hypothesized that a 
NEIL1 deficient mammalian cell line would also accumulate large amounts of Sp 
following exposure to chromate.  Mammalian cells however, unlike E. coli. used in 
previous studies, have three variants of the Nei repair protein, NEIL1, NEIL2, and 
NEIL3.9,10,22  A separate study has demonstrated that NEIL2 has the ability to excise Sp 
lesions in vitro as it was capable of cleaving Sp from single-stranded oligonucleotides.8  
Therefore, while we anticipated that NEIL1 deficient murine epithelial cells would 
accumulate Sp lesions, we also hypothesized that the accumulation may not occur at such 
pronounced levels as was seen in Nei deficient E. coli. as the NEIL1 deficient cell line 
maintains two functional Neil2 alleles.    
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 Sp lesions from E. coli DNA were quantified using a Waters 2790 HPLC coupled 
to a Micromass LCT mass spectrometer with electrospray ionization.21  Unfortunately this 
analysis method was not effective for the NEIL1 epithelial cell lines.  Several problems 
arose that prevented Sp quantification in these cell lines.  The Waters mass spectrometer 
system was a core instrument and as such carried a wide variety of low level 
contaminants from polymers and buffers that had been run through the system.  In order 
to detect Sp in DNA samples, a level of sensitivity in the 1 pmol range had to be reached.  
These low levels of Sp were essentially undetectable when contaminants such as high 
levels of salts were ionized along with the DNA samples.  Another problem with this 
detection set-up was that a C18 reverse phase Microsorb 2.1 mm x 250 mm column was 
used for separation of the DNA bases prior to ionization in the mass spectrometer.  Sp is a 
highly polar molecule and therefore does not interact strongly with a C18 matrix causing 
it to elute rapidly, often so quickly that it emerged in the buffer front.  Another hurdle was 
obtaining large enough quantities of DNA from the epithelial cells for analysis.  The 
ability to grow vast amounts of E. coli. in just 24 hours makes it much easier to obtain 
large quantities of DNA than when one is working with mammalian cells that may take 5 
days to reach confluence.  Low amounts of DNA combined with the inherent problems 
with the mass spectrometer and the C18 column, prevented detection of Sp above 
background using the method previously employed for Sp detection. 
 Methods are being developed using a dedicated Agilent LC/MSD Trap XCT mass 
spectrometer coupled to an Agilent 1200 series HPLC to improve detection limits for Sp 
and Gh lesions in genomic DNA and decreased interference from contaminants within the 
system.  The new methods being developed also use a Thermo Hypercarb 4.6 mm x 150 
mm column for HPLC separation prior to analysis by ion trap mass spectrometry.  
Retention times for Sp on the C18 reverse phase Microsorb column were between 5 and 7 
minutes but on the Thermo Hypercarb column, Sp does not elute until 15 minutes for the 
(-) isomer and 25 minutes for the (+) isomer (Figure 4.11a).  A mobile phase gradient was 
employed over 21 minutes from 99% mobile phase A (deionized water + 0.1% acetic 
acid) and 1% mobile phase B (methanol) to 100% mobile phase B at a constant flow rate 
of 0.9 ml/min.  We are also now able to conduct MS/MS analysis of the 300 molecular 
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weight ion associated with the Sp nucleoside in order to monitor the 184 molecular 
weight ion associated with the Sp free base (Figure 4.11b and 4.12). 
 
     
 
 
Figure 4.11a – Sp isomers from a single stranded oligonucleotide oxidized with Cr(V)-
Salen.  These isomers were separated and detected on an Agilent LC/MSD Trap XCT 
mass spectrometer.  The Sp (+) appears to be the dominant species formed in single 
stranded oligonucleotides and in MCF-7 DNA digests.  
 
 
 
Figure 4.11b – The Sp isomer peaks from (a) both represent ions with a mass to charge 
ratio of 184.  This 184 mass peak generated by free Sp base was obtained by splitting the 
300 mass peak that is generated as the Sp nucleoside moves into the ion trap.  
 
 
 
 Some initial analysis have shown that Sp is present at levels above background in 
hydrolyzed DNA samples from MCF-7 cells exposed to chromate and E2.  Hydrolyzed 
DNA samples from MCF-7 cells were used to look for Sp in our initial ion trap mass 
spectrometry trials for several reasons.  First, these cells grow rapidly making it much 
easier to obtain large amounts of genomic DNA than from the much slower growing 
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NEIL1 epithelial cell lines.  Secondly, a recent report looking at 8-oxoG metabolism in 
MCF-7 cells showed that further oxidized lesions may have been present in MCF-7 cells 
dosed with E2.23  Following exposure to E2, hydrolyzed DNA samples from MCF-7 cells 
were analyzed using HPLC- accelerator mass spectrometry (AMS) and five peaks eluted 
that could not be attributed to 8-oxoG or any of the four natural DNA bases23 indicating 
that further oxidized lesions such as Sp may have been forming.  Of the Sp detected in our 
MCF-7 digests, the Sp(+) isomer appears to be the dominant species present.  The Sp(+) 
isomer also appears to be the dominant species formed in oligonucleotides containing an 
8-oxoG lesion that have been oxidized with Cr(V)-Salen or with Na2IrCl6 (Figure 4.11a).  
This new system for Sp analysis has yet to be applied to DNA digests from the NEIL1 
cell lines but we are hopeful that this system will be effective for detecting Sp at the 1 
pmol level. 
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Figure 4.12 – Mass profile of the Sp nucleoside and the free base. 
 
           
 4.4.2 Implications of the Hprt Mutation Assay The basis for detecting 
mutations in an Hprt mutation assay is resistance to the mutagen 6-TG.  Under normal 
conditions, a cell that is exposed to 6-TG will produce functional copies of hypoxanthine-
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guanine phosphoribosyl transferase (HPRT) which will metabolize 6-TG into a highly 
toxic mutagen.24  As the number of mutations that a cell develops in the Hprt gene 
increases, so do the chances that a non-functional HPRT protein will be produced and 
resistance to 6-TG will ensue as 6-TG will not be metabolized.  For this study, our 
hypothesis was that the Neil1-/- murine epithelial cells should accumulate mutations 
following exposure to chromate as compared to the Neil1+/+ cell line because they have 
an attenuated ability to repair the oxidative lesion Sp.  Therefore, we expected that   Neil1-
/- cells exposed to chromate and then allowed to undergo several rounds of replication 
would show an increased resistance to 6-TG as compared to their wild type counterpart.      
 In order to evaluate whether or not differences in colony formation for the Neil1+/+ 
versus the Neil1-/- cell lines were caused solely by exposure to 6-TG, cells from both lines 
and at all chromate treatment levels needed to be plated in 6-TG-free media to 
simultaneously assess plating efficiencies.  Figure 4.8a-b shows that untreated Neil1+/+ 
and Neil1-/- cells both form similar numbers of colonies when seeded at a density of 400 
cells per 60 mm culture dish and allowed to incubate in 6-TG-free media for 6 days.  
However, exposure to chromate appears to stimulate the growth of the Neil1-/- cells 
whereas it attenuates growth in the Neil1+/+ cell line.  A second control used in this 
experiment was the determination of 6-TG toxicity in both the NEIL1 cell lines.  Using 
the same CellTiter-Blue fluorescence assay described in chapter 3, NEIL1 cells were 
dosed with 6-TG for 24 hours to determine a 50% toxicity level.  Both cell lines reached a 
level of approximately 50% toxicity at a treatment level of 20 µg/ml 6-TG.  One 
drawback to this toxicity assay however, was that it only assessed toxicity on a very short 
time scale.  It did not show whether or not cells would be able to actively replicate 
following treatment with 6-TG but it provided a good starting point for this particular 
assay.   
 Figure 4.9a showed that untreated Neil1+/+ cells were unable to survive over a 
longer time frame (7 days) when exposed to 6-TG at a level of 20 µg/ml.  The untreated 
Neil1-/- cells however, appeared to thrive despite the addition of 6-TG to the media and 
despite the fact that they had a nearly identical plating efficiency as the Neil1+/+ cells.  
This indicated that the Neil1-/- cells may accumulate mutations endogenously even in the 
absence chromate treatment.  There are a large number of oxidants that routinely bombard 
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DNA but the resulting low level of oxidative lesions would be excised and repaired in a 
normal cellular system.  The Neil1-/- cell line does not have a complete base excision 
repair system since the Neil1 gene has been interrupted so it may accumulate some 
oxidative lesions even when not oxidatively stressed with chromate. 
 Figure 4.10 showed that colony formation actually increased over control levels 
for the Neil1-/- cells grown in 6-TG following exposure to increasing concentrations of 
chromate.  It is difficult to say that this increased growth is solely due to increased 6-TG 
resistance because exposure to chromate actually stimulated cell growth as shown in 
figure 4.8a-b.  Some of the increase in colony formation may be attributed to 6-TG 
though, based on the change in growth patterns observed for the 30 and 50 µM chromate 
treatment levels as shown in figure 4.9b.  The Neil1-/- culture flasks for the 0-20 µM 
chromate treatment levels formed colonies in the presence of 6-TG as is typically 
observed when cells are plated at very low densities in mutagen-free media.  Those flasks 
for the 30 and 50 µM chromate treatment levels showed cells growing to confluence in 
the presence of 6-TG as is typically observed when cells are plated at much higher 
densities in mutagen-free media.  This qualitative observation makes it appear as though 
the Neil1-/- cells dosed with the highest chromate concentrations are growing significantly 
better than those dosed with lower chromate concentrations.  Plating efficiencies show 
that growth fell back to control levels after a 50 µM chromate treatment but the 6-TG 
assay indicated that growth in flasks for the 50 µM chromate treatment level were still 
growing better than those at the 20 µM or lower chromate treatment levels.   
 The striking differences in 6-TG toxicity between the two NEIL1 cell lines will 
make it difficult to use a colony formation approach to compare mutation accumulation in 
the two cell lines.  This assay could be repeated using lower 6-TG concentrations in order 
to allow colonies to form in the NEIL1 proficient flasks, but this approach will likely lead 
to overgrowth of the Neil1-/- cells.  Another approach would be to treat the two cell lines 
with different 6-TG concentrations.  However, the best way to move forward from this 
point would most likely be to sequence the Hprt gene in both cell lines and look for 
changes in mutation levels following exposure to chromate and selective growth in the 
presence of 6-TG.  We would expect to see a high number of mutations at guanine 
residues following exposure to chromate.  This approach would also determine whether or 
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not Neil1-/- cells accumulate mutations even under conditions that should not oxidatively 
stress the cells.  However, we would anticipate that these mutations would not be 
concentrated specifically at guanine residues.   
 
 
4.5 Conclusions 
 
 The Neil1-/- cell line has demonstrated a vastly different response to chromate than 
its wild type counterpart.  Chromate is less toxic to the Neil1-/- cells despite the fact that 
they appear to retain some ability to excise Sp (potentially via a NEIL2 pathway).  In 
addition, chromate also stimulates growth in the NEIL1 deficient cell line and can even 
induce apoptosis resistance.  Levels of 8-oxoG are not significantly higher in the Neil1-/- 
cell line following chromate treatment so it stands to reason that the affects that we have 
observed may be linked to further oxidized products.  More specifically, further oxidized 
base lesions since the only part of the genome that has been altered in the Neil1-/- cells is a 
single gene that codes for a BER glycosylase specifically designed for removal of 
oxidized nucleobase lesions.  Mutation accumulation should also be assessed in a more 
specific manner.  Sequencing the Hprt gene to quantify mutations at guanines would 
provide the most conclusive data on this point.  In the big picture, developing a better 
understanding of the role that NEIL1 plays in protecting a cell from oxidative damage 
induced by chromate exposure has the potential to play an important part in preventing 
cancer formation in humans.  We could use our knowledge about NEIL1 to develop 
biomarkers to identify people at high risk and advise them against working in a field 
where chromate exposure is unavoidable.  A better understanding of how chromate can 
induce cancer will also be important as this information would aid in the search for better 
ways to treat those already affected by chromate induced lung carcinomas.          
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